UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-41518
QOMOLANGMA
Acquisition Corp.
(Exact name of registrant as specified in its charter)
Delaware | | 86-3733656 |
(State or Other Jurisdiction of
Incorporation or Organization) | | (I.R.S. Employer
Identification No.) |
1178 Broadway, 3rd Floor New York, NY | | 10001 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code:
(512) 340-7800
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Units | | QOMOU | | The Nasdaq Stock Market LLC |
Common Stock | | QOMO | | The Nasdaq Stock Market LLC |
Warrants | | QOMOW | | The Nasdaq Stock Market LLC |
Rights | | QOMOR | | The Nasdaq Stock Market LLC |
Securities registered pursuant to Section 12(g)
of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer,
as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically
and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒
No ☐
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging
growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | | Accelerated filer ☐ |
Non-accelerated filer ☒ | | Smaller reporting company ☒ |
| | Emerging growth company ☒ |
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether
the registrant has fi led a report on and attestation to its management’s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting fi rm
that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Act). Yes ☒ No ☐
At June 30, 2022, the aggregate market value of the Registrant’s
shares of common stock held by non-affiliates of the Registrant was $0.
The number of shares outstanding of the Registrant’s shares of
common stock as of March 31, 2023 was 6,935,623.
DOCUMENTS INCORPORATED BY REFERENCE
None.
TABLE OF CONTENTS
FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, or the Securities Act, and Section 21E of the Securities Exchange
Act of 1934, or the Exchange Act. Some statements contained in this report are forward-looking in nature. Our forward-looking statements
include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or
circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,”
“plan,” “possible,” “potential,” “predict,” “project,” “should,”
“would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that
a statement is not forward-looking. Forward-looking statements in this report may include, for example, statements about:
| ● | our ability to complete our initial business combination; |
| ● | our success in retaining or recruiting, or changes required
in, our officers, key employees or directors following our initial business combination; |
| ● | our officers and directors allocating their time to other
businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result
of which they would then receive expense reimbursements; |
| ● | our potential ability to obtain additional financing to complete
our initial business combination; |
| ● | our pool of prospective target businesses; |
| ● | the ability of our officers and directors to generate a number
of potential acquisition opportunities; |
| ● | our public securities’ potential liquidity and trading; |
| ● | the lack of a market for our securities; |
| ● | the use of proceeds not held in the trust account or available
to us from interest income on the trust account balance; or |
| ● | our financial performance following our initial public offering. |
The forward-looking statements
contained in this report are based on our current expectations and beliefs concerning future developments and their potential effects
on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements
involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or
performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties
include, but are not limited to, those factors described under the heading “Risk Factors”. Should one or more of these risks
or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
PART
I
Item 1 Business
Qomolangma Acquisition Corp. is a blank check
company incorporated in Delaware on May 6, 2021. We were formed for the purpose of effecting a merger, share exchange, asset acquisition,
stock purchase, reorganization or similar business combination with one or more businesses or entities (“Business Combination”).
We intend to focus on businesses with a total enterprise value of between $300,000,000 and $500,000,000. We will not conduct an initial
business combination with any target company that conducts operations through variable interest entities, or VIEs, or that has an auditor
that the Public Company Accounting Oversight Board, or PCAOB, is unable to inspect for two consecutive years beginning in 2021 at the
time of our business combination.
On October 4, 2022, we consummated our initial public offering (“IPO”)
consisting of 5,000,000 Units (“Public Units”). Each Unit consists of one share of our common stock, par value $0.0001 (the
“Common Stock”), one redeemable warrant, which is exercisable for one share of Common Stock at a price of $11.50 per share,
and one right to receive one-tenth (1/10th) of one share of Common Stock upon the consummation of our initial business combination. We
granted Ladenburg Thalmann & Co. Inc. (“Ladenburg”), the representative of the underwriter, a 45-day option to purchase
up to 750,0000 additional Units to cover over-allotments.
Simultaneously with the closing of the IPO,
we consummated the private placement (the “Private Placement”) with Qomolangma Investments LLC, our sponsor, purchasing
260,500 units (the “Private Units”), generating total proceeds of $2,605,000. The terms of the Private Units are
identical to the Public Units. Additionally, the sponsor agreed not to transfer, assign or sell any of the Private Units or
underlying securities (except in limited circumstances, as described in the registration statement) until the completion of our
initial business combination. The sponsor was granted certain demand and piggyback registration rights in connection with the
purchase of the Private Units.
Simultaneously with the closing, Ladenburg partially exercised its
over-allotment option and the closing of the issuance and sale of the additional Public Units occurred on October 7, 2022. The total issuance
by us of 273,000 Public Units (the “Over-Allotment Option Units”) at price of $10.00 per unit, generated gross proceeds of
$2,730,000. On October 7, 2022, simultaneously with the sale of the Over-Allotment Option Units, we consummated the private sale of an
additional 8,873 Private Units generating gross proceeds of $88,725.
A total of $53,520,950 ($10.15 per Unit) of the net proceeds from the
sale of Public Units in the IPO (including the Over-Allotment Option Units) and the private placements on October 4, 2022 and October
7, 2022, was placed in a trust account maintained for the benefit of the public shareholders at American Stock Transfer & Trust Company,
as a trustee. Except as set forth below, the proceeds held in the trust account will not be released until the earlier of the completion
of our initial business combination and the liquidation due to our failure to complete a business combination within the applicable period
of time. The proceeds deposited in the trust account could become subject to the claims of our creditors, if any, which could have priority
over the claims of our public stockholders. In addition, interest income earned on the investments in the trust account may be released
to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred by us may be paid prior to a business
combination only from the net proceeds of the IPO and private placement not held in the trust account.
Business Strategy
Our efforts in identifying prospective
target businesses will not be limited to a particular geographic region, although we intend to focus on businesses that have a connection
to the Asian market and a total enterprise value of between $300,000,000 and $500,000,000. We believe that we will add value to these
businesses primarily by providing them with access to the U.S. capital markets.
We will seek to capitalize on
the strength of our management team. Our team consists of experienced professionals and senior operating executives. Collectively, our
officers and directors have decades of experience in mergers and acquisitions and operating companies in Asia. We believe we will benefit
from their accomplishments, and specifically their current and recent activities with companies that have a connection to the Asian market,
in identifying attractive acquisition opportunities. However, there is no assurance that we will complete a business combination.
We believe that the members
of our management team and board of directors have valuable and applicable experience for sourcing and analyzing potential acquisition
candidates across various industries and on an international basis based upon their professional experience. Jonathan P. Myers, our
Chairman, President and Chief Executive Officer, has extensive experience in business development and corporate finance in various industries
and nations. Hao Shen, our Chief Financial Officer, has extensive experience in corporate governance and strategic development. Currently
he serves as an independent director and a member of the nominating and compensation committees at Renrui HR (HKG: 6919), a human resource
solutions company which is publicly listed on the Hong Kong Stock Exchange. Jialuan Ma, our independent director, has over 15 years’
experience in financial management and has served as a director in several global companies, including Roche Pharma, Lenovo, Hitachi Vantara
China and Schneider Electric Greater China. Yong Seog Jung, our independent director, has experience in multi-national industry investment
and consulting. He has worked for Hanwha Investment & Securities, which is one of the biggest investment groups in Korea, for
over 10 years. Lin Shi, our independent director, has a professional and academic background in Neurosurgery.
Investment Criteria
Our management team intends
to focus on creating stockholder value by leveraging its experience in the management, operation and financing of businesses to improve
the efficiency of operations while implementing strategies to scale revenue organically and/or through acquisitions. We have identified
the following general criteria and guidelines, which we believe are important in evaluating prospective target businesses. While we intend
to use these criteria and guidelines in evaluating prospective businesses, we may deviate from these criteria and guidelines should we
see justification to do so.
| ● | Middle-Market Growth Business. We
will primarily seek to acquire one or more growth businesses with a total enterprise value of between $300,000,000 and $500,000,000.
We believe that there are a substantial number of potential target businesses within this valuation range that can benefit from new capital
for scalable operations to yield significant revenue and earnings growth. We currently do not intend to acquire either a start-up company
(a company that has not yet established commercial operations) or a company with negative cash flow. |
| ● | Companies in Business Segments that are Strategically
Significant to the Asian Markets. We will seek to acquire those businesses that are currently strategically
significant in the Asian markets. Such sectors include Internet and high technology, financial technology (including technology applied
in financial services or used to help companies manage the financial aspects of their business), clean energy, agriculture machinery,
health care, consumer and retail, energy and resources, food processing, manufacturing and education. |
| ● | Business with Revenue and Earnings Growth Potential. We
will seek to acquire one or more businesses that have the potential for significant revenue and earnings growth through a combination
of both existing and new product development, increased production capacity, expense reduction and synergistic follow-on acquisitions
resulting in increased operating leverage. |
| ● | Companies with Potential for Strong Free Cash Flow
Generation. We will seek to acquire one or more businesses that have the potential to generate strong, stable
and increasing free cash flow. We intend to focus on one or more businesses that have predictable revenue streams and definable low working
capital and capital expenditure requirements. We may also seek to prudently leverage this cash flow in order to enhance stockholder value. |
| ● | Benefit from Being a Public Company. We
intend to only acquire a business or businesses that will benefit from being publicly traded and which can effectively utilize access
to broader sources of capital and a public profile that are associated with being a publicly traded company. |
| ● | Leadership Position. We
will seek to identify one or more companies that have a leadership position in their industry or a defensible niche within a target market
as a result of differentiated technology or other competitive advantages. |
These criteria are not intended
to be exhaustive or exclusive. Any evaluation relating to the merits of a particular business combination may be based, to the extent
relevant, on these general guidelines as well as other considerations, factors and criteria that our sponsor and management team may deem
relevant.
Initial Business Combination
We will have until July 4, 2023 to consummate our initial business
combination. However, if we anticipate that we may not be able to consummate our initial business combination by such date, we may, by
resolution of our board if requested by our sponsor, extend the period of time to consummate a business combination up to twelve times,
each by an additional one month (for a total of up to July 4, 2024 to complete a business combination), subject to the sponsor depositing
additional funds into the trust account as set out below. Pursuant to the terms of our amended and restated certificate of incorporation
and the trust agreement entered into between us and American Stock Transfer & Trust Company, LLC on the date of our
final prospectus for the IPO, in order for the time available for us to consummate our initial business combination to be extended, our
sponsor or its affiliates or designees, upon five days advance notice prior to the applicable deadline, must deposit into the trust
account $174,009 (approximately $0.033 per public share per month), up to an aggregate of $2,088,108, or approximately $0.40 per public
share (for an aggregate of 12 months), on or prior to the date of the applicable deadline, for each extension. In the event that
we receive notice from our sponsor five days prior to the applicable deadline of its wish for us to effect an extension, we intend
to issue a press release announcing such intention at least three days prior to the applicable deadline. In addition, we intend to
issue a press release the day after the applicable deadline announcing whether or not the funds had been timely deposited. Our sponsor
and its affiliates or designees are not obligated to fund the trust account to extend the time for us to complete our initial business
combination. If we are unable to consummate our initial business combination within the applicable time period, we will, as promptly as
reasonably possible but not more than ten business days thereafter, redeem the public shares for a pro rata portion of the funds
held in the trust account and as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders
and our board of directors, dissolve and liquidate, subject in each case to our obligations under Delaware law to provide for claims of
creditors and the requirements of other applicable law. In such event, the warrants and rights will be worthless.
Our sponsor may extend the time frame by the company to complete a
business combination up to July 4, 2024 by depositing the required amount of funds for each monthly extension. Holders of our securities
will not have to right to approve or disapprove any such monthly extension. Further, holders of our securities will not have the right
to seek or obtain redemption in connection with any extension of the time frame to complete a business combination.
Any such payments from our sponsor
to extend the time frame would be made in the form of a loan from our sponsor to the company. The final and definitive terms of the loan
in connection with any such loans have not yet been negotiated, but any such loan would be interest free and not repaid unless and until
we complete a business combination. If we complete our initial business combination, we would expect to repay such loaned amounts out
of the proceeds of the trust account released to us or from funds which may be raised in any subsequent capital financing transaction
which may be undertaken in connection with the completion of a business combination.
The Nasdaq rules require that
our initial business combination must be with one or more target businesses that together have an aggregate fair market value equal to
at least 80% of the balance in the trust account (less any deferred underwriting commissions and taxes payable on interest earned) at
the time of our signing a definitive agreement in connection with our initial business combination. If our Board of Directors is not able
to independently determine the fair market value of the target business or businesses, we will obtain an opinion from an independent investment
banking firm or another independent firm that commonly renders valuation opinions for the type of company we are seeking to acquire or
an independent accounting firm. We do not intend to purchase multiple businesses in unrelated industries in conjunction with our initial
business combination. If we are delisted from Nasdaq prior to completion of the business combination, the Nasdaq 80% requirement would
no longer be applicable.
We anticipate structuring our
initial business combination so that the post-transaction company in which our public stockholders own shares will own or acquire 100%
of the equity interests or assets of the target business or businesses. The determination of whether or not to acquire less than 100%
of the equity interests or assets will be dependent upon numerous factors, including satisfaction of certain objectives of the target
management team or target’s stockholders, the costs of any such proposed acquisition or for other reasons, many of which we cannot
determine at this time and will be contingent upon negotiations with prospective targets. We may, however, structure our initial business
combination such that the post-transaction company owns or acquires less than 100% of such interests or assets of the target business
in order to meet certain objectives of the target management team or stockholders or for other reasons, but we will only complete a business
combination for equity interests if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of
the target or otherwise acquires a controlling interest in the target or in the event of an assets acquisition, an acquisition which results
in an operating business line, sufficient for it not to be required to register as an investment company under the Investment Company
Act of 1940, as amended, or the Investment Company Act. In considering an asset transaction, we would acquire such assets only
if we could constitute from such assets a stand-alone operating business. Even if the post-transaction company owns or acquires 50% or
more of the voting securities of the target, our stockholders prior to the business combination may collectively own a minority interest
in the post-transaction company, depending on valuations ascribed to the target and us in the business combination transaction. For example,
we could pursue a transaction in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock
of a target. In this case, we would acquire a 100% controlling interest in the target. However, as a result of the issuance of a substantial
number of new shares, our stockholders immediately prior to our initial business combination could own less than a majority of our outstanding
shares subsequent to our initial business combination. If less than 100% of the equity interests or assets of a target business or businesses
are owned or acquired by the post-transaction company, the portion of such business or businesses that is owned or acquired is what will
be valued for purposes of the 80% of Nasdaq net assets test. If our initial business combination involves more than one target business
or assets from different business, the 80% of net assets test will be based on the aggregate value of all of the target businesses.
Corporate Information
Status as a Public Company
We believe our structure will
make us an attractive business combination partner to target businesses. As an existing public company, we offer a target business an
alternative to the traditional initial public offering through a merger or other business combination. In this situation, the owners of
the target business would exchange their shares of stock in the target business for our shares or for a combination of our shares and
cash, allowing us to tailor the consideration to the specific needs of the sellers. Although there are various costs and obligations associated
with being a public company, we believe target businesses will find this method a more certain and cost effective method to becoming a
public company than the typical initial public offering. In a typical initial public offering, there are additional expenses incurred
in marketing, road show and public reporting efforts that may not be present to the same extent in connection with a business combination
with us.
Furthermore, once a proposed
business combination is completed, the target business will have effectively become public, whereas an initial public offering is always
subject to the underwriters’ ability to complete the offering, as well as general market conditions, which could delay or prevent
the offering from occurring. Once public, we believe the target business would then have greater access to capital and an additional means
of providing management incentives consistent with stockholders’ interests. It can offer further benefits by augmenting a company’s
profile among potential new customers and vendors and aid in attracting talented employees.
While we believe that our structure
and our management team’s backgrounds will make us an attractive business partner, some potential target businesses may have a negative
view of us since we are a blank check company, without an operating history, and there is uncertainty relating to our ability to obtain
stockholder approval of our proposed initial business combination and retain sufficient funds in our trust account in connection therewith.
We are an “emerging growth company,” as defined in the
JOBS Act. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following
the fifth anniversary of the completion of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion
or (c) in which we are deemed to be a large accelerated filer, which means the market value of our shares of common stock that is
held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued
more than $1.0 billion in non-convertible debt securities during the prior three-year period.
Financial Position
With funds available for a business combination initially in the amount
of $53,520,950 (including the Over-Allotment Option Units and the over-allotment Private Units) assuming no redemptions and after payment
of $2,109,200 of deferred underwriting fees, in each case before fees and expenses associated with our initial business combination, we
offer a target business a variety of options such as creating a liquidity event for its owners, providing capital for the potential growth
and expansion of its operations or strengthening its balance sheet by reducing its debt ratio. Because we are able to complete our initial
business combination using our cash, debt or equity securities, or a combination of the foregoing, we have the flexibility to use the
most efficient combination that will allow us to tailor the consideration to be paid to the target business to fit its needs and desires.
However, we have not taken any steps to secure third party financing and there can be no assurance it will be available to us.
Effecting Our Initial Business Combination
We are not presently engaged
in, and we will not engage in, any operations for an indefinite period of time. We intend to effectuate our initial business combination
using cash from the proceeds of our IPO and the private placement of the private placement units, our shares, debt or a combination of
these as the consideration to be paid in our initial business combination. We may, although we do not currently intend to, seek to complete
our initial business combination with a company or business that may be financially unstable or in its early stages of development or
growth, start-up companies or companies with speculative business plans or excess leverage, which would subject us to the numerous risks
inherent in such companies and businesses.
If our initial business combination
is paid for using equity or debt securities, or not all of the funds released from the trust account are used for payment of the consideration
in connection with our initial business combination or used for redemptions of our shares of common stock, we may apply the balance of
the cash released to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of
the post-transaction company, the payment of principal or interest due on indebtedness incurred in completing our initial business combination,
to fund the purchase of other companies or for working capital.
We may seek to raise additional
funds through a private offering of debt or equity securities in connection with the completion of our initial business combination, and
we may effectuate our initial business combination using the proceeds of such offering rather than using the amounts held in the trust
account.
In the case of an initial business
combination funded with assets other than the trust account assets, our tender offer documents or proxy materials disclosing the business
combination would disclose the terms of the financing and, only if required by law, we would seek stockholder approval of such financing.
There are no prohibitions on our ability to raise funds privately or through loans in connection with our initial business combination.
At this time, we are not a party to any arrangement or understanding with any third party with respect to raising any additional funds
through the sale of securities or otherwise.
Selection of a Target Business and Structuring
of Our Initial Business Combination
The Nasdaq rules require that
our initial business combination must be with one or more target businesses that together have an aggregate fair market value equal to
at least 80% of the balance in the trust account (less any deferred underwriting commissions and taxes payable on interest earned) at
the time of our signing a definitive agreement in connection with our initial business combination. The fair market value of the target
or targets will be determined by our Board of Directors based upon one or more standards generally accepted by the financial community,
such as discounted cash flow valuation or value of comparable businesses. Our stockholders will be relying on the business judgment of
our Board of Directors, which will have significant discretion in choosing the standard used to establish the fair market value of the
target or targets, and different methods of valuation may vary greatly in outcome from one another. Such standards used will be disclosed
in our tender offer documents or proxy solicitation materials, as applicable, related to our initial business combination. In the event
that we were delisted from Nasdaq prior to completion of a business combination, we would not be subject to the Nasdaq rule requiring
our initial business combination must be with one or more target businesses that together have an aggregate fair market value equal to
at least 80% of the balance in the trust account.
If our board is not able to
independently determine the fair market value of the target business or businesses, we will obtain an opinion from an independent investment
banking firm or another independent firm that commonly renders valuation opinions for the type of company we are seeking to acquire or
an independent accounting firm, with respect to the satisfaction of such criteria. We do not intend to purchase multiple businesses in
unrelated industries in conjunction with our initial business combination. Subject to this requirement, our management will have virtually
unrestricted flexibility in identifying and selecting one or more prospective target businesses, although we will not be permitted to
effectuate our initial business combination with another blank check company or a similar company with nominal operations.
In any case, we will only complete
an initial business combination in which we own or acquire 50% or more of the outstanding voting securities of the target or otherwise
acquire a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment
Company Act. If we own or acquire less than 100% of the equity interests or assets of a target business or businesses, the portion of
such business or businesses that are owned or acquired by the post-transaction company is what will be valued for purposes of the 80%
of net assets test.
To the extent we effect our
initial business combination with a company or business that may be financially unstable or in its early stages of development or growth
we may be affected by numerous risks inherent in such company or business.
In evaluating a prospective
target business, we expect to conduct a thorough due diligence review which will encompass, among other things, meetings with incumbent
management and employees, document reviews, inspection of facilities, as well as a review of financial, operational, legal and other information
which will be made available to us.
The time required to select
and evaluate a target business and to structure and complete our initial business combination, and the costs associated with this process,
are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification and evaluation of
a prospective target business with which our initial business combination is not ultimately completed will result in our incurring losses
and will reduce the funds we can use to complete another business combination.
Lack of Business Diversification
For an indefinite period of
time after the completion of our initial business combination, the prospects for our success may depend entirely on the future performance
of a single business. Unlike other entities that have the resources to complete business combinations with multiple entities in one or
several industries, it is probable that we will not have the resources to diversify our operations and mitigate the risks of being in
a single line of business. By completing our initial business combination with only a single entity, our lack of diversification may:
| ● | subject us to negative economic, competitive and regulatory
developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial
business combination; and |
| ● | cause us to depend on the marketing and sale of a single
product or limited number of products or services. |
Limited Ability to Evaluate the Target’s
Management Team
Although we intend to closely
scrutinize the management of a prospective target business when evaluating the desirability of effecting our initial business combination
with that business, our assessment of the target business’s management may not prove to be correct. In addition, the future management
may not have the necessary skills, qualifications or abilities to manage a public company. Furthermore, the future role of members of
our management team, if any, in the target business cannot presently be stated with any certainty. While it is possible that one or more
of our directors will remain associated in some capacity with us following our initial business combination, it is unlikely that any of
them will devote their full efforts to our affairs subsequent to our initial business combination. Moreover, we cannot assure you that
members of our management team will have significant experience or knowledge relating to the operations of the particular target business.
We cannot assure you that any
of our key personnel will remain in senior management or advisory positions with the combined company. The determination as to whether
any of our key personnel will remain with the combined company will be made at the time of our initial business combination.
Following a business combination,
we may seek to recruit additional managers to supplement the incumbent management of the target business. We cannot assure you that we
will have the ability to recruit additional managers, or that such additional managers will have the requisite skills, knowledge or experience
necessary to enhance the incumbent management.
Stockholders May Not Have the Ability to
Approve Our Initial Business Combination
We may conduct redemptions without
a stockholder vote pursuant to the tender offer rules of the SEC subject to the provisions of our amended and restated certificate of
incorporation. However, we will seek stockholder approval if it is required by law or applicable stock exchange rule, or we may decide
to seek stockholder approval for business or other legal reasons.
Under the Nasdaq’s listing
rules, stockholder approval would be required for our initial business combination if, for example:
| ● | we issue shares of common stock that will be equal to or
in excess of 20% of the number of shares of common stock then issued and outstanding (other than in a public offering); |
| ● | any of our directors, officers or substantial stockholders
(as defined by Nasdaq rules) has a 5% or greater interest (or such persons collectively have a 10% or greater interest), directly or
indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of shares of common stock
could result in an increase in issued and outstanding shares of common stock or voting power of 5% or more; or |
| ● | the issuance or potential issuance of shares of common stock
will result in our undergoing a change of control. |
Permitted Purchases of Our Securities
In the event we seek stockholder approval of our initial business combination
and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor,
directors, officers, advisors or their affiliates may purchase shares in privately negotiated transactions or in the open market either
prior to or following the completion of our initial business combination. There is no limit on the number of shares such persons may purchase.
However, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions
for any such transactions. In the event our sponsor, directors, officers, advisors or their affiliates determine to make any such purchases
at the time of a stockholder vote relating to our initial business combination, such purchases could have the effect of influencing the
vote necessary to approve such transaction. None of the funds in the trust account will be used to purchase shares in such transactions.
They will not make any such purchases when they are in possession of any material non-public information not disclosed to the seller or
if such purchases are prohibited by Regulation M under the Exchange Act. Such a purchase may include a contractual acknowledgement
that such stockholder, although still the record holder of our shares is no longer the beneficial owner thereof and therefore agrees not
to exercise its redemption rights. We will adopt an insider trading policy which will require insiders to: (i) refrain from purchasing
shares during certain blackout periods and when they are in possession of any material non-public information and (ii) to clear all
trades with our legal counsel prior to execution. We cannot currently determine whether our insiders will make such purchases pursuant
to a Rule 10b5-1 plan, as it will be dependent upon several factors, including but not limited to, the timing and size of such purchases.
Depending on such circumstances, our insiders may either make such purchases pursuant to a Rule 10b5-1 plan or determine that such
a plan is not necessary.
In the event that our sponsor, directors, officers, advisors or their
affiliates purchase shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption
rights, such selling stockholders would be required to revoke their prior elections to redeem their shares. We do not currently anticipate
that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the Exchange Act or a going-private
transaction subject to the going-private rules under the Exchange Act; however, if the purchasers determine at the time of any such
purchases that the purchases are subject to such rules, the purchasers will comply with such rules.
The purpose of such purchases
would be to (i) vote such shares in favor of the business combination and thereby increase the likelihood of obtaining stockholder
approval of the business combination or (ii) to satisfy a closing condition in an agreement with a target that requires us to have
a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement
would otherwise not be met. This may result in the completion of our initial business combination that may not otherwise have been possible.
In addition, if such purchases
are made, the public “float” of our shares of common stock may be reduced and the number of beneficial holders of our securities
may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities
exchange.
Our sponsor, officers, directors,
advisors and/or their affiliates anticipate that they may identify the stockholders with whom our sponsor, officers, directors, advisors
or their affiliates may pursue privately negotiated purchases by either the stockholders contacting us directly or by our receipt of redemption
requests submitted by stockholders following our mailing of proxy materials in connection with our initial business combination. To the
extent that our sponsor, officers, directors or their affiliates enter into a private purchase, they would identify and contact only potential
selling stockholders who have expressed their election to redeem their shares for a pro rata share of the trust account or vote against
the business combination. Such persons would select the stockholders from whom to acquire shares based on the number of shares available,
the negotiated price per share and such other factors as any such person may deem relevant at the time of purchase. The price per share
paid in any such transaction may be different than the amount per share a public stockholder would receive if it elected to redeem its
shares in connection with our initial business combination. Our sponsor, officers, directors, advisors or their affiliates will only purchase
shares if such purchases comply with Regulation M under the Exchange Act and the other federal securities laws.
Any purchases by our sponsor,
officers, directors, advisors and/or their affiliates who are affiliated purchasers under Rule 10b-18 under the Exchange Act
will only be made to the extent such purchases are able to be made in compliance with Rule 10b-18, which is a safe harbor from liability
for manipulation under Section 9(a)(2) and Rule 10b-5 of the Exchange Act. Rule 10b-18 has certain technical
requirements that must be complied with in order for the safe harbor to be available to the purchaser. Our sponsor, officers, directors,
advisors and/or their affiliates will not make purchases of shares of common stock if the purchases would violate Section 9(a)(2) or
Rule 10b-5 of the Exchange Act.
Ability to Extend Time to Complete Business
Combination
We will have until July 4, 2023 to consummate our initial business
combination. However, if we anticipate that we may not be able to consummate our initial business combination by such date, we may, by
resolution of our board if requested by our sponsor, extend the period of time to consummate a business combination up to twelve times,
each by an additional one month (for a total of up to July 4, 2024 to complete a business combination), subject to the sponsor depositing
additional funds into the trust account as set out below. Pursuant to the terms of our amended and restated certificate of incorporation
and the trust agreement entered into between us and American Stock Transfer & Trust Company, LLC on the date of our
final prospectus for the IPO, in order for the time available for us to consummate our initial business combination to be extended, our
sponsor or its affiliates or designees, upon five days advance notice prior to the applicable deadline, must deposit into the trust
account $174,009 (approximately $0.033 per public share per month), up to an aggregate of $2,088,108, or approximately $0.40 per public
share (for the entire 12 month period), on or prior to the date of the applicable deadline, for each extension. In the event that
we receive notice from our sponsor five days prior to the applicable deadline of its wish for us to effect an extension, we intend
to issue a press release announcing such intention at least three days prior to the applicable deadline. In addition, we intend to
issue a press release the day after the applicable deadline announcing whether or not the funds had been timely deposited. Our sponsor
and its affiliates or designees are not obligated to fund the trust account to extend the time for us to complete our initial business
combination.
Our sponsor may extend the time
frame for us to complete a business combination by up to an additional 12 months contingent upon our sponsor timely depositing the
required amount of funds for each monthly extension. Holders of our securities will not have to right to approve or disapprove any such
monthly extension. Further, holders of our securities will not have the right to seek or obtain redemption in connection with any extension
of the time frame.
Any such payments from our sponsor
to extend the time frame would be made in the form of a loan from our sponsor. The final and definitive terms of the loan in connection
with any such loans have not yet been negotiated, but any such loan would be interest free and not repaid unless and until we complete
a business combination. If we complete our initial business combination, we would expect to repay such loaned amounts out of the proceeds
of the trust account released to us or from funds which may be raised in any subsequent capital financing transaction which may be undertaken
in connection with the completion of a business combination.
Redemption Rights for Public Stockholders
upon Completion of Our Initial Business Combination
We will provide our public stockholders with the opportunity to redeem
all or a portion of their shares of common stock upon the completion of our initial business combination at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in the trust account as of two business days prior to the consummation of
the initial business combination, including interest (which interest shall be net of taxes payable) divided by the number of then issued
and outstanding public shares, subject to the limitations described herein. The amount in the trust account is initially anticipated to
be approximately $10.15 per public share (subject to increase of up to an additional $0.40 per public share in the event that our sponsor
elects to extend the period of time to consummate a business combination, as described in more detail herein). The per-share amount we
will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay
to the underwriters. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed
to waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may hold in
connection with the completion of our initial business combination.
Manner of Conducting Redemptions
We will provide our public stockholders
with the opportunity to redeem all or a portion of their shares of common stock upon the completion of our initial business combination
either (i) in connection with a stockholder meeting called to approve the business combination or (ii) by means of a tender
offer. Stockholders will not be granted any right to redeem their securities in connection with any decision by us to extend the time
frame to complete a business combination from 9 months to up to 21 months. The decision as to whether we will seek stockholder
approval of a proposed business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based
on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek stockholder
approval under the law or stock exchange listing requirement. Under Nasdaq rules, asset acquisitions and stock purchases would not typically
require stockholder approval while direct mergers with our company where we do not survive and any transactions where we issue more than
20% of our issued and outstanding shares of common stock or seek to amend our amended and restated certificate of incorporation would
require stockholder approval. We intend to conduct redemptions without a stockholder vote pursuant to the tender offer rules of the SEC
unless stockholder approval is required by law or stock exchange listing requirement or we choose to seek stockholder approval for business
or other legal reasons. So long as we obtain and maintain a listing for our securities on the Nasdaq, we will be required to comply with
Nasdaq rules.
If a stockholder vote is not
required and we do not decide to hold a stockholder vote for business or other legal reasons, we will, pursuant to our amended and restated
certificate of incorporation:
| ● | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E
of the Exchange Act, which regulate issuer tender offers; and |
| ● | file tender offer documents with the SEC prior to completing
our initial business combination which contain substantially the same financial and other information about the initial business combination
and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
Upon the public announcement
of our initial business combination, we or our sponsor will terminate any plan established in accordance with Rule 10b5-1 to purchase
our shares of common stock in the open market if we elect to redeem our public shares through a tender offer, to comply with Rule 14e-5
under the Exchange Act.
In the event we conduct redemptions
pursuant to the tender offer rules, our offer to redeem will remain open for at least 20 business days, in accordance with Rule 14e-1(a) under
the Exchange Act, and we will not be permitted to complete our initial business combination until the expiration of the tender offer
period. In addition, the tender offer will be conditioned on public stockholders not tendering more than a specified number of public
shares which are not purchased by our sponsor, which number will be based on the requirement that we may not redeem public shares in an
amount that would cause our net tangible assets, after payment of the deferred underwriting commissions, to be less than $5,000,001 upon
consummation of our initial business combination (so that we are not subject to the SEC’s “penny stock” rules) or any
greater net tangible asset or cash requirement which may be contained in the agreement relating to our initial business combination. If
public stockholders tender more shares than we have offered to purchase, we will withdraw the tender offer and not complete the initial
business combination.
If, however, stockholder approval
of the transaction is required by law or stock exchange listing requirement, or we decide to obtain stockholder approval for business
or other legal reasons, we will, pursuant to our amended and restated certificate of incorporation:
| ● | conduct the redemptions in conjunction with a proxy solicitation
pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender
offer rules; and |
| ● | file proxy materials with the SEC. |
We expect that a final proxy
statement would be mailed to public stockholders at least 10 days prior to the stockholder vote. However, we expect that a draft
proxy statement would be made available to such stockholders well in advance of such time, providing additional notice of redemption if
we conduct redemptions in conjunction with a proxy solicitation. Although we are not required to do so, we currently intend to comply
with the substantive and procedural requirements of Regulation 14A in connection with any stockholder vote even if we are not able
to maintain our Nasdaq listing or Exchange Act registration.
In the event that we seek stockholder
approval of our initial business combination, we will distribute proxy materials and, in connection therewith, provide our public stockholders
with the redemption rights described above upon completion of the initial business combination.
If we seek stockholder approval, we will complete our initial business
combination only if a majority of the issued and outstanding shares of common stock voted are voted in favor of the business combination.
In such case, pursuant to the terms of a letter agreement entered into with us, our sponsor, officers and directors have agreed (and their
permitted transferees will agree) to vote any founder shares and private placement shares held by them and any public shares purchased
during or after the IPO in favor of our initial business combination. We expect that at the time of any stockholder vote relating to our
initial business combination, our sponsor and its permitted transferees will own approximately 21.50% of our issued and outstanding shares
of common stock entitled to vote thereon (assuming it does not purchase units in the IPO, and taking into account ownership of the private
placement units). Each public stockholder may elect to redeem their public shares irrespective of whether they vote for or against the
proposed transaction. In addition, our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which
they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and public shares in
connection with the completion of a business combination.
Our amended and restated certificate
of incorporation provides that in no event will we redeem our public shares in an amount that would cause our net tangible assets to be
less than $5,000,001 upon consummation of our initial business combination (so that we are not subject to the SEC’s “penny
stock” rules). Redemptions of our public shares may also be subject to a higher net tangible asset test or cash requirement pursuant
to an agreement relating to our initial business combination. For example, the proposed business combination may require: (i) cash
consideration to be paid to the target or its owners, (ii) cash to be transferred to the target for working capital or other general
corporate purposes or (iii) the retention of cash to satisfy other conditions in accordance with the terms of the proposed business
combination. In the event the aggregate cash consideration we would be required to pay for all shares of common stock that are validly
submitted for redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed business combination
exceed the aggregate amount of cash available to us, we will not complete the business combination or redeem any shares, and all shares
of common stock submitted for redemption will be returned to the holders thereof.
Limitation on Redemption upon Completion
of Our Initial Business Combination if We Seek Stockholder Approval
Notwithstanding the foregoing,
if we seek stockholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business
combination pursuant to the tender offer rules, our amended and restated certificate of incorporation provides that a public stockholder,
together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group”
(as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to Excess
Shares. We believe this restriction will discourage stockholders from accumulating large blocks of shares, and subsequent attempts by
such holders to use their ability to exercise their redemption rights against a proposed business combination as a means to force us or
our sponsor or its affiliates to purchase their shares at a significant premium to the then-current market price or on other undesirable
terms. Absent this provision, a public stockholder holding more than an aggregate of 15% of the shares sold in the IPO could threaten
to exercise its redemption rights if such holder’s shares are not purchased by us or our sponsor or its affiliates at a premium
to the then-current market price or on other undesirable terms. By limiting our stockholders’ ability to redeem no more than 15%
of the shares sold in the IPO, we believe we will limit the ability of a small group of stockholders to unreasonably attempt to block
our ability to complete our initial business combination, particularly in connection with a business combination with a target that requires
as a closing condition that we have a minimum net worth or a certain amount of cash. However, we would not be restricting our stockholders’
ability to vote all of their shares (including Excess Shares) for or against our initial business combination. Our sponsor, officers and
directors have, pursuant to a letter agreement entered into with us, waived their right to have any founder shares or public shares held
by them redeemed in connection with our initial business combination. Unless any of our other affiliates acquires founder shares through
a permitted transfer from an initial stockholder, and thereby becomes subject to the letter agreement, no such affiliate is subject to
this waiver. However, to the extent any such affiliate acquired public shares in the IPO or thereafter through open market purchases,
it would be a public stockholder and restricted from seeking redemption rights with respect to any Excess Shares.
Tendering Share Certificates in Connection
with a Tender Offer or Redemption Rights
We may require our public stockholders
seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street name,” to either
tender their certificates (if any) to our transfer agent prior to the date set forth in the tender offer documents, or up to two business
days prior to the vote on the proposal to approve the business combination in the event we distribute proxy materials, or to deliver their
shares to the transfer agent electronically using The Depository Trust Company’s DWAC (Deposit/ Withdrawal At Custodian) System,
rather than simply voting against the initial business combination. The tender offer or proxy materials, as applicable, that we will furnish
to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public stockholders
to satisfy such delivery requirements. Accordingly, a public stockholder would have from the time we send out our tender offer materials
until the close of the tender offer period, or up to two days prior to the vote on the business combination if we distribute proxy
materials, as applicable, to tender its shares if it wishes to seek to exercise its redemption rights. Pursuant to the tender offer rules,
the tender offer period will be not less than 20 business days and, in the case of a stockholder vote, a final proxy statement would
be mailed to public stockholders at least 10 days prior to the stockholder vote. However, we expect that a draft proxy statement
would be made available to such stockholders well in advance of such time, providing additional notice of redemption if we conduct redemptions
in conjunction with a proxy solicitation. Given the relatively short exercise period, it is advisable for stockholders to use electronic
delivery of their public shares.
There is a nominal cost associated
with the above-referenced tendering process and the act of certificating the shares or delivering them through the DWAC System. The transfer
agent will typically charge the tendering broker $80.00 and it would be up to the broker whether or not to pass this cost on to the redeeming
holder. However, this fee would be incurred regardless of whether or not we require holders seeking to exercise redemption rights to tender
their shares. The need to deliver shares is a requirement of exercising redemption rights regardless of the timing of when such delivery
must be effectuated.
The foregoing is different from
the procedures used by many blank check companies. In order to perfect redemption rights in connection with their business combinations,
many blank check companies would distribute proxy materials for the stockholders’ vote on an initial business combination, and a
holder could simply vote against a proposed business combination and check a box on the proxy card indicating such holder was seeking
to exercise his or her redemption rights. After the business combination was approved, the company would contact such stockholder to arrange
for him or her to deliver his or her certificate to verify ownership. As a result, the stockholder then had an “option window”
after the completion of the business combination during which he or she could monitor the price of the company’s shares in the market.
If the price rose above the redemption price, he or she could sell his or her shares in the open market before actually delivering his
or her shares to the company for cancellation. As a result, the redemption rights, to which stockholders were aware they needed to commit
before the stockholder meeting, would become “option” rights surviving past the completion of the business combination until
the redeeming holder delivered its certificate. The requirement for physical or electronic delivery prior to the meeting ensures that
a redeeming holder’s election to redeem is irrevocable once the business combination is approved.
Any request to redeem such shares,
once made, may be withdrawn at any time up to the date set forth in the tender offer materials or the date of the stockholder meeting
set forth in our proxy materials, as applicable. Furthermore, if a holder of a public share delivered its certificate in connection with
an election of redemption rights and subsequently decides prior to the applicable date not to elect to exercise such rights, such holder
may simply request that the transfer agent return the certificate (physically or electronically). It is anticipated that the funds to
be distributed to holders of our public shares electing to redeem their shares will be distributed promptly after the completion of our
initial business combination.
If our initial business combination
is not approved or completed for any reason, then our public stockholders who elected to exercise their redemption rights would not be
entitled to redeem their shares for the applicable pro rata share of the trust account. In such case, we will promptly return any certificates
delivered by public holders who elected to redeem their shares.
If our initial proposed business combination is not completed, we may
continue to try to complete a business combination with a different target until July 4, 2023 (or up to July 4, 2024 if we extend the
period of time to consummate a business combination, as described in more detail herein).
Redemption of Public Shares and Liquidation
if No Initial Business Combination
Our sponsor, officers and directors have agreed that we will have only
until July 4, 2023 (or up to July 4, 2024 if we extend the period of time to consummate a business combination, as described in more detail
herein) to complete our initial business combination. If we are unable to complete our initial business combination within such time period,
we will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more
than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount
then on deposit in the trust account, including interest (less up to $50,000 of interest to pay dissolution expenses (which interest shall
be net of taxes payable) divided by the number of then issued and outstanding public shares, which redemption will completely extinguish
public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject
to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining
stockholders and our Board of Directors, liquidate and dissolve, subject in each case to our obligations under Delaware law to provide
for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions
with respect to our warrants or rights, which will expire worthless if we fail to complete our initial business combination within the
9-month (or up to 21-month) time period.
Our sponsor may extend the time
frame for us to complete a business combination by up to an additional 12 months contingent upon our sponsor timely depositing into
the trust account the required amount of funds for each monthly extension. Holders of our securities will not have to right to approve
or disapprove any such monthly extension. Further, holders of our securities will not have the right to seek or obtain redemption in connection
with any extension of the time frame to complete a business combination.
Any such payments from our sponsor
to extend the time frame would be made in the form of a loan from our sponsor. The final and definitive terms of the loan in connection
with any such loans have not yet been negotiated, but any such loan would be interest free and not repaid unless and until we complete
a business combination. If we complete our initial business combination, we would expect to repay such loaned amounts out of the proceeds
of the trust account released to us or from funds which may be raised in any subsequent capital financing transaction which may be undertaken
in connection with the completion of a business combination.
Our sponsor, officers and directors have entered into a letter agreement
with us, pursuant to which they have waived their rights to liquidating distributions from the trust account with respect to their founder
shares and private placement shares if we fail to complete our initial business combination within 9 months from the closing of the
IPO (or up to 21 months from the closing of the IPO if we extend the period of time to consummate a business combination, as described
in more detail herein). However, if our sponsor acquires public shares after the IPO, they will be entitled to liquidating distributions
from the trust account with respect to such public shares if we fail to complete our initial business combination within the allotted
9-month (or up to 21-month) time period.
Our sponsor, officers and directors have agreed, pursuant to a written
letter agreement with us, that they will not propose any amendment to our amended and restated certificate of incorporation that would
(i) modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our initial business
combination within 9 months from the closing of the IPO (or up to 21 months from the closing of the IPO if we extend the period
of time to consummate a business combination, as described in more detail herein) or (ii) with respect to the other provisions relating
to stockholders’ rights or pre-business combination activity, unless we provide our public stockholders with the opportunity to
redeem their shares of common stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the trust account, including interest (which interest shall be net of taxes payable) divided by the number of
then issued and outstanding public shares. However, we may not redeem our public shares in an amount that would cause our net tangible
assets to be less than $5,000,001 upon consummation of our initial business combination (so that we are not subject to the SEC’s
“penny stock” rules). If this optional redemption right is exercised with respect to an excessive number of public shares
such that we cannot satisfy the net tangible asset requirement (described above), we would not proceed with the amendment or the related
redemption of our public shares.
We expect that all costs and
expenses associated with implementing our plan of dissolution, as well as payments to any creditors, will be funded from amounts remaining
out of the $500,000 of proceeds held outside the trust account, although we cannot assure you that there will be sufficient funds for
such purpose. However, if those funds are not sufficient to cover the costs and expenses associated with implementing our plan of dissolution,
to the extent that there is any interest accrued in the trust account not required to pay taxes, we may request the trustee to release
to us an additional amount of up to $50,000 of such accrued interest to pay those costs and expenses.
If we were to expend all of the net proceeds of the IPO and the sale
of the private placement units, other than the proceeds deposited in the trust account, and without taking into account interest, if any,
earned on the trust account, the per-share redemption amount received by stockholders upon our dissolution would be approximately $10.15
(subject to increase of up to an additional $0.40 per public share in the event that our sponsor elects to extend the period of time to
consummate a business combination, as described in more detail herein). The proceeds deposited in the trust account could, however, become
subject to the claims of our creditors which would have higher priority than the claims of our public stockholders. We cannot assure you
that the actual per-share redemption amount received by stockholders will not be substantially less than $10.15. While we intend to pay
such amounts, if any, we cannot assure you that we will have funds sufficient to pay or provide for all creditors’ claims.
Although we will seek to have
all vendors, service providers, prospective target businesses or other entities with which we do business execute agreements with us waiving
any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public stockholders,
there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from
bringing claims against the trust account including but not limited to fraudulent inducement, breach of fiduciary responsibility or other
similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with respect
to a claim against our assets, including the funds held in the trust account. If any third party refuses to execute an agreement waiving
such claims to the monies held in the trust account, our management will perform an analysis of the alternatives available to it and will
only enter into an agreement with a third party that has not executed a waiver if management believes that such third party’s engagement
would be significantly more beneficial to us than any alternative. Examples of possible instances where we may engage a third party that
refuses to execute a waiver include the engagement of a third party consultant whose particular expertise or skills are believed by management
to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable
to find a service provider willing to execute a waiver.
In addition, there is no guarantee
that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts
or agreements with us and will not seek recourse against the trust account for any reason. Upon redemption of our public shares, if we
are unable to complete our initial business combination within the prescribed time frame, or upon the exercise of a redemption right in
connection with our initial business combination, we will be required to provide for payment of claims of creditors that were not waived
that may be brought against us within the 10 years following redemption. Our sponsor has agreed that it will be liable to us if and
to the extent any claims by a vendor for services rendered or products sold to us, or a prospective target business with which we have
discussed entering into a transaction agreement, reduce the amount of funds in the trust account to below (i) $10.15 per public share
or (ii) such lesser amount per public share held in the trust account as of the date of the liquidation of the trust account, due
to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as
to any claims by a third party who executed a waiver of any and all rights to seek access to the trust account and except as to any claims
under our indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. In the
event that an executed waiver is deemed to be unenforceable against a third party, then our sponsor will not be responsible to the extent
of any liability for such third-party claims. We have not independently verified whether our sponsor has sufficient funds to satisfy their
indemnity obligations and believe that our sponsor’s only assets are securities of our company. None of our other officers will
indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses.
In the event that the proceeds
in the trust account are reduced below (i) $10.15 per public share or (ii) such lesser amount per public share held in the trust
account as of the date of the liquidation of the trust account, due to reductions in value of the trust assets, in each case net of the
amount of interest which may be withdrawn to pay taxes, and our sponsor asserts that it is unable to satisfy its indemnification obligations
or that it has no indemnification obligations related to a particular claim, our independent directors would determine whether to take
legal action against our sponsor to enforce its indemnification obligations. While we currently expect that our independent directors
would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible that our independent
directors in exercising their business judgment may choose not to do so in any particular instance. Accordingly, we cannot assure you
that due to claims of creditors the actual value of the per-share redemption price will not be substantially less than $10.15 per share.
We will seek to reduce the possibility
that our sponsor will have to indemnify the trust account due to claims of creditors by endeavoring to have all vendors, service providers,
prospective target businesses or other entities with which we do business execute agreements with us waiving any right, title, interest
or claim of any kind in or to monies held in the trust account. Our sponsor will also not be liable as to any claims under our indemnity
of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. We will have access to up
to $500,000 from the proceeds of the IPO and the sale of the private placement units, with which to pay any such potential claims (including
costs and expenses incurred in connection with our liquidation, currently estimated to be no more than approximately $50,000).
If we file a bankruptcy petition
or an involuntary bankruptcy petition is filed against us that is not dismissed, the proceeds held in the trust account could be subject
to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over
the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account, we cannot assure you we will be able to
return $10.15 per share to our public stockholders. Additionally, if we file a bankruptcy petition or an involuntary bankruptcy petition
is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor
and/or bankruptcy laws as either a “preferential transfer” or a “fraudulent conveyance.” As a result, a bankruptcy
court could seek to recover all amounts received by our stockholders. Furthermore, our board may be viewed as having breached its fiduciary
duty to our creditors and/or may have acted in bad faith, and thereby exposing itself and our company to claims of punitive damages, by
paying public stockholders from the trust account prior to addressing the claims of creditors. We cannot assure you that claims will not
be brought against us for these reasons.
Our public stockholders will be entitled to receive funds from the
trust account only upon the earlier of (i) the completion of our initial business combination, (ii) the redemption of any public
shares properly tendered in connection with a stockholder vote to amend our amended and restated certificate of incorporation (A) to
modify the substance or timing of our obligation to redeem 100% of our public shares if we do not complete our initial business combination
by July 4, 2023 (or up to July 4, 2024 if we extend the period of time to consummate a business combination, as described in more detail
herein) or (B) with respect to any other provision relating to stockholders’ rights or pre-business combination activity and
(iii) the redemption of all of our public shares if we are unable to complete our initial business combination by July 4, 2023 (or
up to July 4, 2024 if we extend the period of time to consummate a business combination, as described in more detail herein), subject
to applicable law. In no other circumstances will a stockholder have any right or interest of any kind to or in the trust account. In
the event we seek stockholder approval in connection with our initial business combination, a stockholder’s voting in connection
with the business combination alone will not result in a stockholder’s redeeming its shares to us for an applicable pro rata share
of the trust account. Such stockholder must have also exercised its redemption rights described above.
Competition
In identifying, evaluating and
selecting a target business for our initial business combination, we may encounter competition from other entities having a business objective
similar to ours, including other blank check companies, private equity groups and leveraged buyout funds, and operating businesses seeking
strategic business combinations. Many of these entities are well established and have extensive experience identifying and effecting business
combinations directly or through affiliates. Moreover, many of these competitors possess greater financial, technical, human and other
resources than we do. Our ability to acquire larger target businesses will be limited by our available financial resources. This inherent
limitation gives others an advantage in pursuing the initial business combination of a target business. Furthermore, our obligation to
pay cash in connection with our public stockholders who exercise their redemption rights may reduce the resources available to us for
our initial business combination and our outstanding warrants, and the future dilution they potentially represent, may not be viewed favorably
by certain target businesses. Either of these factors may place us at a competitive disadvantage in successfully negotiating an initial
business combination.
Employees
We currently have two officers.
These individuals are not obligated to devote any specific number of hours to our matters but they intend to devote as much of their time
as they deem necessary to our affairs until we have completed our initial business combination. The amount of time they will devote in
any time period will vary based on whether a target business has been selected for our initial business combination and the stage of the
initial business combination process we are in. We do not intend to have any full-time employees prior to the completion of our initial
business combination.
Periodic Reporting and Financial
Information
We have registered our units,
Common Stock, warrants and rights under the Exchange Act and have reporting obligations, including the requirement that we file annual,
quarterly and current reports with the SEC. In accordance with the requirements of the Exchange Act, our annual reports will contain financial
statements audited and reported on by our independent registered public accountants.
We will provide stockholders with audited financial statements of the
prospective target business as part of the tender offer materials or proxy solicitation materials sent to stockholders to assist them
in assessing the target business. In all likelihood, these financial statements will need to be prepared in accordance with, or reconciled
to, U.S. GAAP, or IFRS, depending on the circumstances, and the historical financial statements may be required to be audited in accordance
with the standards of the PCAOB. These financial statement requirements may limit the pool of potential targets we may conduct an initial
business combination with because some targets may be unable to provide such statements in time for us to disclose such statements in
accordance with federal proxy rules and complete our initial business combination within the prescribed time frame. We cannot assure you
that any particular target business identified by us as a potential business combination candidate will have financial statements prepared
in accordance with U.S. GAAP or that the potential target business will be able to prepare its financial statements in accordance with
the requirements outlined above. To the extent that these requirements cannot be met, we may not be able to acquire the proposed target
business. While this may limit the pool of potential business combination candidates, we do not believe that this limitation will be material.
We will be required to evaluate our internal control procedures for
the fiscal year ending December 31, 2023 as required by the Sarbanes-Oxley Act. Only in the event we are deemed to be a large accelerated
filer or an accelerated filer, and no longer qualify as an emerging growth company, will we be required to have our internal control procedures
audited. A target company may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of their internal
controls. The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the
time and costs necessary to complete any such business combination. We filed a registration statement on Form 8-A with the SEC to voluntarily
register our securities under Section 12 of the Exchange Act. As a result, we are subject to the rules and regulations promulgated under
the Exchange Act. We have no current intention of filing a Form 15 to suspend our reporting or other obligations under the Exchange Act
prior or subsequent to the consummation of our initial business combination.
Item
1A. Risk Factors
As a smaller reporting company, we are not required to make disclosures
under this Item. However, for a list of risk factors relating to our operations, see the section titled “Risk Factors” contained
in our registration statement on Form S-1 (File No. 333-265447) filed in connection with our IPO.
Item
1B. Unresolved Staff Comments
Not applicable.
Item
2. Properties
We currently maintain
our principal executive offices at 1178 Broadway, 3rd Floor, New York, NY 10010. The cost for this space is included in the
$10,000 per month fee that we pay to our sponsor, Qomolangma Investments LLC. We consider our current office space, combined with the
other office space otherwise available to our executive officers, adequate for our current operations.
Item
3. Legal Proceedings
We may be subject
to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. We are not currently a party
to any material litigation or other legal proceedings brought against us. We are also not aware of any legal proceeding, investigation
or claim, or other legal exposure that has a more than remote possibility of having a material adverse effect on our business, financial
condition or results of operations.
Item
4. Mine Safety Disclosures
Not Applicable.
PART
II
Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our units began to trade
on The Nasdaq Stock Market LLC, or Nasdaq, under the symbol “QOMOU” on October 4, 2022. The shares of Common Stock, warrants
and rights comprising the units began separate trading on Nasdaq on November 25, 2022, under the symbols “QOMO”, “QOMOW”
and “QOMOR”, respectively.
Holders of Record
As of December 31, 2022,
there were 6,935,623 of our shares of Common Stock issued and outstanding held by 9 shareholders of record. The number of record holders
was determined from the records of our transfer agent and does not include beneficial owners of shares of Common Stock whose shares are
held in the names of various security brokers, dealers, and registered clearing agencies.
Dividends
We have not paid any
cash dividends on our Common Stock to date and do not intend to pay cash dividends prior to the completion of an initial business combination.
The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general
financial condition subsequent to completion of a business combination. The payment of any dividends subsequent to a business combination
will be within the discretion of our board of directors at such time. It is the present intention of our board of directors to retain
all earnings, if any, for use in our business operations and, accordingly, our board of directors does not anticipate declaring any dividends
in the foreseeable future. In addition, our board of directors is not currently contemplating and does not anticipate declaring any share
dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive
covenants we may agree to in connection therewith.
Securities Authorized
for Issuance Under Equity Compensation Plans
None.
Recent Sales of Unregistered
Securities
On September 25,
2021, we issued 1,437,500 shares of common stock or founder shares to our sponsor for an aggregate purchase price of $25,000, or approximately
$0.0174 per share. Of the 1,437,500 founder shares that were issued and outstanding, up to 187,500 shares were subject to forfeiture by
the sponsor to the extent that the underwriters’ over-allotment is not exercised in full, so that the sponsor would collectively
own 20% of our issued and outstanding shares after the IPO (assuming the sponsor did not purchase any Public Units in the IPO and excluding
the Private Units). As a result of the underwriters’ partial exercise of their over-allotment option on October 4, 2022, 119,250
of the founder shares were forfeited for no consideration on October 7, 2022 resulting in 1,318,250 founder shares outstanding after the
forfeiture.
On October 4, 2022, simultaneously with the closing of the IPO, our
sponsor purchased an aggregate of 260,500 private placement units at a price of $10.00 per Private Unit for an aggregate purchase price
of $2,605,000. Simultaneously with the closing of the over-allotment option, we issued an additional 8,873 Private Units to the sponsor
at a price of $10.00 per Private Unit, generating total proceeds of $88,725. Each Private Unit consists of one private placement share,
one private placement right granting the holder thereof the right to receive one-tenth (1/10) of a share of common stock upon the consummation
of an initial business combination, and one private placement warrant. Each private placement warrant entitles the holder upon exercise
to purchase one share of common stock at a price of $11.50 per share, subject to adjustment as provided herein. The Private Units (including
the underlying securities) may not, subject to certain limited exceptions, be transferred, assigned or sold by it until 30 days after
the completion of our initial business combination.
Use of Proceeds
On October 4, 2022, we consummated our IPO consisting of 5,000,000
Units (“Public Units”). Each Unit consists of one share of our common stock, par value $0.0001 (the “Common Stock”),
one redeemable warrant, which is exercisable for one share of Common Stock at a price of $11.50 per share, and one right to receive one-tenth
(1/10th) of one share of Common Stock upon the consummation of our initial business combination. We granted Ladenburg Thalmann & Co.
Inc. (“Ladenburg”), the representative of the underwriter, a 45-day option to purchase up to 750,0000 additional Units to
cover over-allotments.
Simultaneously with
the closing of the IPO, we consummated the private placement (the “Private Placement”) with Qomolangma Investments LLC, our
sponsor, purchasing 260,500 units (the “Private Units”), generating total proceeds of $2,605,000. The terms of the Private
Units are identical to the Public Units. Additionally, the sponsor agreed not to transfer, assign or sell any of the Private Units or
underlying securities (except in limited circumstances, as described in the registration statement) until the completion of our initial
business combination. The sponsor was granted certain demand and piggyback registration rights in connection with the purchase of the
Private Units.
Simultaneously with the closing, Ladenburg partially exercised its
over-allotment option and the closing of the issuance and sale of the Over-Allotment Option Units occurred on October 7, 2022. The total
issuance by us of 273,000 Over-Allotment Option Units at price of $10.00 per unit, generated gross proceeds of $2,730,000. On October
7, 2022, simultaneously with the sale of the Over-Allotment Option Units, we consummated the private sale of an additional 8,873 Private
Units generating gross proceeds of $88,725.
A total of $53,520,950 ($10.15 per Unit) of the net proceeds from the
sale of Public Units in the IPO (including the Over-Allotment Option Units) and the private placements on October 4, 2022 and October
7, 2022, was placed in a trust account maintained for the benefit of the public shareholders at American Stock Transfer & Trust Company,
as a trustee. Except as set forth below, the proceeds held in the trust account will not be released until the earlier of the completion
of our initial business combination and the liquidation due to our failure to complete a business combination within the applicable period
of time. The proceeds deposited in the trust account could become subject to the claims of our creditors, if any, which could have priority
over the claims of our public stockholders. In addition, interest income earned on the investments in the trust account may be released
to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred by us may be paid prior to a business
combination only from the net proceeds of the IPO and private placement not held in the trust account.
We paid a total of $922,775
in underwriting discounts and commissions (not including the 4.00% deferred underwriting commission payable at the consummation of business
combination) and $540,530 for other costs and expenses related to the IPO.
For a description of
the use of the proceeds generated in our IPO, see below Part II, Item 7 – Management’s Discussion and Analysis
of Financial Condition and Results of Operations of this Form 10-K.
Purchases of Equity
Securities by the Issuer and Affiliated Purchasers
None.
Item
6. [RESERVED]
As a smaller reporting
company, we are not required to make disclosures under this Item.
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our audited financial statements
and the notes related thereto which are included in “Item 8. Financial Statements and Supplementary Data” of this Annual
Report on Form 10-K. Certain information contained in the discussion and analysis set forth below includes forward-looking statements.
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including
those set forth under “Special Note Regarding Forward-Looking Statements,” “Item 1A. Risk Factors” and elsewhere
in this Annual Report on Form 10-K.Certain information contained in the discussion and analysis set forth below includes forward-looking
statements that involve risks and uncertainties.
Special Note Regarding
Forward-Looking Statements
This Annual Report includes
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities
Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical
facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All
statements, other than statements of historical fact included in this Quarterly Report, including, without limitation, statements in
this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the search for
an initial business combination, the Company’s financial position, business strategy and the plans and objectives of management
for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,”
“intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify
such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s
current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ
materially from the events, performance and results discussed in the forward-looking statements. For information identifying important
factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to
the Risk Factors section of the Company’s final prospectus for its initial public offering filed with the U.S. Securities and Exchange
Commission (the “SEC”). The Company’s filings with the SEC can be accessed on the EDGAR section of the SEC’s
website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation
to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Overview
We are a blank check
company incorporated in Delaware on May 6, 2021. We were formed for the purpose of entering into a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses, which we refer
to herein as our “initial business combination.” Our efforts to identify a prospective target business are not limited to
any particular industry or geographic region, although we intend to pursue target businesses that are strategically significant in the
Asian markets and focus on businesses with a total enterprise value of between $300,000,000 and $500,000,000. We intend to utilize cash
derived from the proceeds of our initial public offering (“IPO” as defined below) and the private placement of Private Units,
our securities, debt or a combination of cash, securities and debt, in effecting our initial business combination.
We expect to continue
to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete an initial business
combination will be successful.
Results of Operations
We have neither engaged
in any operations nor generated any operating revenues to date. Our only activities through December 31, 2022 were organizational activities
and those necessary to prepare for our IPO, which is described below, and subsequent to the IPO, identifying a target company for an
initial business combination. We do not expect to generate any operating revenues until after the completion of our initial business
combination.
We expect to generate non-operating income in the form of interest
income on investments held in the trust account after the IPO. We expect that we will incur increased expenses as a result of being a
public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection
with searching for, and completing, a Business Combination.
For the year ended December 31, 2022, we had a net income of $134,851,
which consists of loss of approximately $220,601 derived from general and administrative expenses of approximately $174,673, franchise
tax expense of $45,928, income tax expense of $46,115, and deferred income tax expense of $36,164, offset by interest earned on investments
held in the trust account of approximately $265,522.
For the year ended December
31, 2022, there was $351,050 of cash used in operating activities.
For the period from
May 6, 2021 (inception) through December 31, 2021, we had a net loss of $3,935, all of which consisted of formation costs.
Liquidity, Capital
Resources and Going Concern
On October 4, 2022, we completed our IPO of 5,000,000 units (the “Public
Units”), at $10.00 per Public Unit, generating gross proceeds of $50,000,000. Each Public Unit consisted of one share of common
stock, par value $0.0001, one redeemable warrant and one right to receive one-tenth (1/10) of a share of common stock upon the consummation
of an initial business combination. Simultaneously with the closing of the IPO, we completed the sale of 260,500 units (the “Private
Units”) in a private placement, at a price of $10.00 per Private Unit, generating gross proceeds of $2,605,000.
We granted the underwriters in the IPO a 45-day option to purchase
up to 750,000 additional Public Units to cover over-allotments, if any. On October 4, 2022, the underwriters partially exercised the over-allotment
option to purchase 273,000 Over-Allotment Option Units at $10.00 per Unit, which closed on October 7, 2022 generating total gross proceeds
of $2,730,000. On October 7, 2022, simultaneously with the sale of the Over-Allotment Option Units, the Company consummated the private
placement of an additional 8,873 Private Units generating gross proceeds of $88,725. Simultaneously with the closing of the IPO, we issued
Ladenburg Thalmann & Co., Inc., the underwriter, 75,000 shares of common stock.
Following the IPO and the private placement (including the Over-Allotment
Option Units and the Over-Allotment Private Units), a total of $53,520,950 was placed in a trust account located in the United States
established for the benefit of the Company’s public stockholders (the “Trust Account”) maintained by American Stock
Transfer & Trust Company as a trustee and will be invested only in U.S. government treasury bills with a maturity of 185 days or less
or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, and that invest
only in direct U.S. government treasury obligations.
We intend to use substantially
all of the net proceeds of the IPO and the private placement, including the funds held in the Trust Account, in connection with our initial
business combination and to pay our expenses relating thereto, including deferred underwriting discounts and commissions payable to the
underwriters in the IPO in an amount equal to 4.0% of the total gross proceeds raised in the IPO upon consummation of our initial business
combination. To the extent that our capital stock is used in whole or in part as consideration to effect our initial business combination,
the remaining proceeds held in the Trust Account as well as any other net proceeds not expended will be used as working capital to finance
the operations of the target business. Such working capital funds could be used in a variety of ways including continuing or expanding
the target business’ operations, for strategic acquisitions and for marketing, research and development of existing or new products.
Such funds could also be used to repay any operating expenses or finders’ fees which we had incurred prior to the completion of
our initial business combination if the funds available to us outside of the Trust Account were insufficient to cover such expenses.
As of December 31, 2022, the Company had $196,510 of cash held outside
its trust account and a working capital of $152,362 (excluding income tax and franchise tax payable). On March 22, 2023, the Sponsor loaned
the Company $200,000, to be used, in part, for transaction costs related to the Business Combination. The Company has until July 4,
2023 (or up to July 4, 2024 if the time to complete a business combination is extended as described herein) to consummate a Business Combination.
It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business Combination is not consummated
by this date, there will be a mandatory liquidation and subsequent dissolution.
The Company expects to continue to incur significant
professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of
a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it
becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company
may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities
laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is
unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations
and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need
to obtain additional financing in order to meet its obligations.
In connection with the Company’s assessment
of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”)
2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined
that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company
is unable to complete a Business Combination within the Combination Period, the Company’s board of directors would proceed to commence
a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate
a Business Combination will be successful within the Combination Period. As a result, management has determined that such additional condition
also raise substantial doubt about the Company’s ability to continue as a going concern. The financial statement does not include
any adjustments that might result from the outcome of this uncertainty.
Off-Balance Sheet
Arrangements
We have no obligations, assets or liabilities, which would be considered
off-balance sheet arrangements as of December 31, 2022 and December 31, 2021. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
Contractual Obligations
We do not have any long-term
debt, capital lease obligations, operating lease obligations or long-term liabilities, other than described below.
Administrative Services Agreement
We have entered into an administrative services
agreement pursuant to which we will pay the Sponsor a total of $10,000 per month (subject to deferral as described herein) for office
space, utilities, secretarial and administrative support services. Upon completion of our initial business combination or our liquidation,
we will cease paying these monthly fees.
Registration Rights
The holders of the founder shares, private placement units, and units
that may be issued on conversion of working capital loans (and any securities underlying the private placement units and the working capital
loans) are entitled to registration rights pursuant to a registration rights agreement signed on the effective date of the IPO requiring
us to register such securities for resale. The holders of these securities are entitled to make up to three demands, excluding short form
demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect
to registration statements filed subsequent to our completion of our initial business combination and rights to require us to register
for resale such securities pursuant to Rule 415 under the Securities Act. We will bear the expenses incurred in connection with the
filing of any such registration statements.
Underwriting Agreement
Pursuant to an underwriting agreement in connection with the IPO, we
granted Ladenburg Thalmann, the representative of the underwriters, a 45-day option to purchase up to 750,000 additional Units to cover
over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On October 4, 2022, the underwriters partially
exercised the over-allotment option to purchase 273,000 units at an offering price of $10.00 per Unit for an aggregate purchase price
of $2,730,000.
The underwriters were paid a cash underwriting discount of 1.75% of
the gross proceeds of the IPO, or $922,775. In addition, the underwriters are entitled to a deferred fee of 4.00% of the gross proceeds
of the IPO, or $2,109,200, which will be paid upon the closing of a Business Combination from the amounts held in the Trust Account, subject
to the terms of the underwriting agreement.
Critical Accounting
Policies
The preparation of financial statements and related disclosures in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the period reported.
Actual results could materially differ from those estimates. We have identified the following critical accounting policies:
Common Stock Subject
to Possible Redemption
We account for our common stock subject to possible conversion in accordance
with the guidance in Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.”
Common stock subject to mandatory redemption is classified as a liability instrument and measured at fair value. Conditionally redeemable
common stock (including common stock that features redemption rights that are either within the control of the holder or subject to redemption
upon the occurrence of uncertain events not solely within our control) is classified as temporary equity. At all other times, common stock
is classified as stockholders’ equity. Our common stock features certain redemption rights that are considered to be outside of
our control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented
at redemption value as temporary equity, outside of the stockholders’ equity section of our balance sheets. We made a policy election
in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in accumulated deficit over an expected 9-month period
leading up to a Business Combination.
Warrants
The Company accounts for warrants as either equity-classified or liability-classified
instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting
Standards Board Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and
Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to
ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity
classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the
warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Consequently, the Company
accounts for warrants as equity-classified instruments.
For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated
fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations.
Net Income (Loss)
Per Share
The Company complies
with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. In order to determine the net income (loss) attributable
to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both
the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends
paid. We then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between the
redeemable and non-redeemable shares. Any re-measurement of the accretion to redemption value of the common shares subject to possible
redemption was considered to be dividends paid to the public shareholders.
Offering Costs
Offering costs were
consisting principally of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are related
to the IPO and were charged to stockholders’ equity upon the completion of the IPO. The Company allocates offering costs between
public shares, public warrants and public rights based on the relative fair values of public shares, public warrants and public rights.
Recent accounting
pronouncements
In August 2020, FASB issued Accounting Standards Update (“ASU”)
2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s
Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates
the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies
the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard
also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s
own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all
convertible instruments. ASU 2020-06 is effective January 1, 2024 for the Company and should be applied on a full or modified retrospective
basis, with early adoption permitted beginning on January 1, 2021. The Company is currently assessing the impact, if any, that ASU 2020-06
would have on its financial position, results of operations or cash flows.
Management does not
believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material
effect on the Company’s financial statement.
Item
7A. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting
company, we are not required to make disclosures under this Item.
Item
8. Financial Statements and Supplementary Data
This information appears
following Item 15 of this report and is included herein by reference.
Item
9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.
Based on information provided by Friedman LLP
(“Friedman”), our independent registered public accounting firm, effective September 1, 2022, Friedman combined with Marcum
LLP (“Marcum”) and continued to operate as an independent registered public accounting firm. Friedman continued to serve as
our independent registered public accounting firm through October 19, 2022. On October 18, 2022, the Audit Committee of the Board of Directors
of the company dismissed Friedman and engaged Marcum to serve as our independent registered public accounting firm for the year ended
December 31, 2022. The services previously provided by Friedman are now provided by Marcum.
Friedman’s reports on the company’s
financial statements for the period from May 6, 2021 (inception) through December 31, 2021 (the “Audit Report”) did not contain
an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles,
except that the Audit Report contained an uncertainty about the company’s ability to continue as a going concern.
During the period from May 6, 2021 (inception)
through December 31, 2021, and the subsequent interim period through October 19, 2022, there were no disagreements with Friedman on any
matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if
not resolved to the satisfaction of Friedman, would have caused Friedman to make reference to the subject matter of the disagreements
in connection with its reports on the company’s financial statements for such years. Also during this time, there were no “reportable
events,” as defined in Item 304(a)(1)(v) of Regulation S-K.
On October 19, 2022, we engaged Marcum as our independent registered
public accounting firm for the fiscal year ending December 31, 2022, effective immediately. During the period from May 6, 2021 (inception)
through October 19, 2022, neither the company nor anyone on its behalf consulted with Marcum regarding (i) the application of accounting
principles to any specified transaction, either completed or proposed or the type of audit opinion that might be rendered on the company’s
financial statements, and neither a written report nor oral advice was provided to the company that Marcum concluded was an important
factor considered by the company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter
that was either the subject of a “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K, or a “reportable
event,” as defined in Item 304(a)(1)(v) of Regulation S-K.
Item
9A. Controls and Procedures
Evaluation of Disclosure
Controls and Procedures
Disclosure controls and procedures are designed to ensure that information
required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified
in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive
officer and chief financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure.
Under the supervision and with the participation of our management,
including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our disclosure controls
and procedures as of the fiscal year ended December 31, 2022, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act. Based on this evaluation, our chief executive officer and chief financial officer have concluded that during the period covered by
this report, our disclosure controls and procedures were effective.
Changes in Internal
Control Over Financial Reporting
During the quarter ended
December 31, 2022, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably
likely to materially affect, our internal control over financial reporting.
Management’s Report on Internal Controls
Over Financial Reporting
This Annual Report on Form 10-K does not include
a report of management’s assessment regarding internal control over financial reporting or an attestation report of our independent
registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.
Changes in Internal Control over Financial
Reporting
There were no changes
in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during
the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over
financial reporting.
Item
9B. Other information.
None.
Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
PART
III
Item
10. Directors, Executive Officers and Corporate Governance
The following table sets forth
information about our directors and executive officers.
Name |
|
Age1 |
|
Position |
Jonathan P. Myers |
|
59 |
|
Chairman, President and Chief
Executive Officer |
Hao Shen |
|
51 |
|
Chief Financial Officer and Director |
Jialuan Ma |
|
49 |
|
Director |
Yong Seog Jung |
|
58 |
|
Director |
Lin Shi |
|
40 |
|
Director |
Below is a summary of the business experience
of each of our executive officers and directors:
Jonathan P. Myers
has been Chairman of our Board of Directors and our President and Chief Executive Officer since August 2021. He has served as a
partner with responsibility for cross border corporate development and transactions at Ventac Partners, which focuses on ventures in
life sciences, since 2008. From May 2001 to March 2006, he served as director of business development at Pain Therapeutics,
Inc., which later was renamed Cassava Sciences. Mr. Myers received his MBA from Rotterdam School of Management Erasmus University
in 1994. We believe Mr. Myers is well qualified to serve on our board of directors because of his extensive experience in business development
and corporate finance in various industries and nations.
Hao Shen has
been our Chief Financial Officer and a member of our Board of Directors since August 2021. He has served as an independent director
at NCH Huayang since August 2013. His responsibilities cover corporate governance and strategic development. In addition, he also
has served as the founder and managing director of Shanghai Zhaohui Network Technology Co., Ltd since December 2014 and an independent
director and member of the nomination and compensation committees at Renrui HR (HKG: 6919) since December 2019. From November 2010
to July 2013, he served as the managing director at H&Q Asia Pacific Investment. Mr. Shen received his B.A. degree from
Gustavus Adolphus College in 1995 and Master of Education from Harvard University in 1997. We believe Mr. Shen is well qualified to serve
on our board of directors because of his extensive operational, management and financial experience, as well as his contacts and relationships.
Jialuan Ma has served
as an independent director on our Board of Directors since August 2021. Ms. Ma has extensive experience relating to financial management
and as a director. She is also a certified investment management analyst, since 1998. She served as the financial director for Roche
Pharma China in Shanghai from August 2019 to April 2021. From December 2017 to August 2018, she served as global
financial director for Lenovo. From November 2014 to November 2017, she served as finance director of mainland China and Taiwan
at Hitachi Vantara China. From September 2013 to March 2014, she served as central FP&A controller for Schneider Electric
Greater China. She received her undergraduate degree in English and Economics from Shanghai Jiao Tong University in 1991, an MBA from
Richmond Business School in 1998 and a Master of Science from City University of Hong Kong in 2013. We believe Ms. Ma is well qualified
to serve on our board of directors because of her extensive financial and management experience, as well as her contacts and relationships.
Yong Seog Jung
has served as an independent director on our Board of Directors since August 2021. Mr. Jung has an extensive multi-national
investment and consulting background. He has served as the chief executive officer of Hochang Business Consulting Co., Ltd since March 2017.
From January 2014 to January 2017, he served as vice general manager and head of the Korea department at Shanghai Choki International.
From January 2011 to December 2013, he served as the chief representative of the Shanghai office of Hanwha Investment &
Securities Co., Ltd, one of the biggest investment groups in Korea. From July 2010 to December 2010, he served as the chief
executive officer of Hanwha (Shanghai) Investment & Consulting Co, Ltd. From July 2004 to July 2010, he served as
the general manager of Hanwha Investment Securities Co. Mr. Jung received a B.A. degree in Business Administration from Feng Chia
University in 1990. We believe Mr. Jung is well qualified to serve on our board of directors because of his extensive experience in multi-national
investments and consulting, as well as his contacts and relationships.
1 | Confirm the age of each director and officer. |
Lin Shi has served as
an independent director on our Board of Directors since August 2021. He has a professional and academic background in neurosurgery.
He has served as associate senior neurosurgeon in the department of neurosurgery at Beijing Tiantan Hospital since December 2019.
From December 2017 to November 2019, he served as attending neurosurgeon in the department of neurosurgery at Beijing Tiantan
Hospital. From December 2017 to December 2018, he was a visiting scholar at Stanford University’s Center for Neurological
Disorders and Neuroscience. Mr. Shi received his Ph.D. in Neurosurgery from Capital Medical University in 2015, an M.D. of Clinical
Medicine from Harbin Medical University in 2009 and an M.M. in Clinical Medicine from Harbin Medical University in 2009. We believe Mr.
Shi is well qualified to serve on our board of directors because of his extensive professional and academic experience in neurosurgery.
Number, Terms of Office and Election of
Officers and Directors
Our Board of Directors consists
of five (5) members. Each of our directors will hold office for a two-year term. Subject to any other special rights applicable
to the stockholders, any vacancies on our Board of Directors may be filled by the affirmative vote of a majority of the directors present
and voting at the meeting of our board or by a majority of the holders of our founder shares.
Our officers are elected by
the Board of Directors and serve at the discretion of the Board of Directors, rather than for specific terms of office. Our Board of
Directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws provide that our
officers may consist of a Chairman, Chief Executive Officer, President, Chief Financial Officer, Vice Presidents, Secretary, Assistant
Secretaries, Treasurer and such other offices as may be determined by the Board of Directors.
Director Independence
The Nasdaq listing standards
require that a majority of our Board of Directors be independent. An “independent director” is defined generally as a person
who has no material relationship with the listed company (either directly or as a partner, stockholder or officer of an organization
that has a relationship with the company). We have three “independent directors” as defined in the Nasdaq listing standards
and applicable SEC rules. Our board has determined that each of Messrs. Yong Seog Jung, Lin Shi and Ms. Jialuan Ma are independent directors
under applicable SEC and Nasdaq rules. Following the completion of our initial public offering, our independent directors will have regularly
scheduled meetings at which only independent directors are present.
Committees of the Board of Directors
Our Board of Directors has three standing committees: an audit committee,
a compensation committee and a nominating committee. Each committee operates under a charter that has been approved by our board and will
have the composition and responsibilities described below. Subject to phase-in rules and a limited exception, Nasdaq rules and Rule 10A-3
of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors, and Nasdaq
rules require that the compensation committee of a listed company be comprised solely of independent directors.
Audit Committee
We have established an audit
committee of the Board of Directors. The members of our audit committee are Messrs. Yong Seog Jung, Lin Shi and Jialuan Ma, each of whom
is an independent director under Nasdaq listing rules. Jialuan Ma serves as chairman of the audit committee.
Each member of the audit committee
is financially literate and our Board of Directors has determined that Jialuan Ma qualifies as an “audit committee financial expert”
as defined in applicable SEC rules.
We have adopted an audit committee
charter, which details the principal functions of the audit committee, including:
| ● | the appointment, compensation, retention,
replacement, and oversight of the work of the independent auditors and any other independent
registered public accounting firm engaged by us; |
| ● | pre-approving all audit and non-audit
services to be provided by the independent auditors or any other registered public accounting
firm engaged by us, and establishing pre-approval policies and procedures; |
| ● | reviewing and discussing with the
independent auditors all relationships the auditors have with us in order to evaluate their
continued independence; |
| ● | setting clear hiring policies for
employees or former employees of the independent auditors; |
| ● | setting clear policies for audit
partner rotation in compliance with applicable laws and regulations; |
| ● | obtaining and reviewing a report,
at least annually, from the independent auditors describing (i) the independent auditor’s
internal quality-control procedures and (ii) any material issues raised by the most
recent internal quality-control review, or peer review, of the audit firm, or by any inquiry
or investigation by governmental or professional authorities, within, the preceding five years
respecting one or more independent audits carried out by the firm and any steps taken to
deal with such issues; |
| ● | reviewing and approving any related
party transaction required to be disclosed pursuant to Item 404 of Regulation S-K
promulgated by the SEC prior to us entering into such transaction; and |
| ● | reviewing with management, the independent
auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters,
including any correspondence with regulators or government agencies and any employee complaints
or published reports that raise material issues regarding our financial statements or accounting
policies and any significant changes in accounting standards or rules promulgated by the
Financial Accounting Standards Board, the SEC or other regulatory authorities. |
Compensation Committee
We have established a compensation
committee of the Board of Directors. The members of our Compensation Committee are Messrs. Yong Seog Jung, Lin Shi and Jialuan Ma, each
of whom is an independent director under Nasdaq listing rules. Jialuan Ma serves as chairman of the compensation committee. We have adopted
a compensation committee charter, which details the principal functions of the compensation committee, including:
| ● | reviewing and approving on an annual
basis the corporate goals and objectives relevant to our Chief Executive Officer’s
compensation, evaluating our Chief Executive Officer’s performance in light of such
goals and objectives and determining and approving the remuneration (if any) of our Chief
Executive Officer’s based on such evaluation; |
| ● | reviewing and approving the compensation
of all of our other officers; |
| ● | reviewing our executive compensation
policies and plans; |
| ● | implementing and administering our
incentive compensation equity-based remuneration plans; |
| ● | assisting management in complying
with our proxy statement and annual report disclosure requirements; |
| ● | approving all special perquisites,
special cash payments and other special compensation and benefit arrangements for our officers
and employees; |
| ● | producing a report on executive compensation
to be included in our annual proxy statement; and |
| ● | reviewing, evaluating and recommending
changes, if appropriate, to the remuneration for directors. |
The charter also provides that
the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other
adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before
engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee
will consider the independence of each such adviser, including the factors required by the Nasdaq and the SEC.
Nominating Committee
We have established a nominating
committee of the board of directors, which consists of Messrs. Yong Seog Jung, Lin Shi and Jialuan Ma, each of whom is an independent
director under Nasdaq listing rules. Jialuan Ma serves as chairman of the nominating committee. The nominating committee is responsible
for overseeing the selection of persons to be nominated to serve on our board of directors. The nominating committee considers persons
identified by its members, management, stockholders, investment bankers and others.
Guidelines for Selecting Director Nominees
The guidelines for selecting
nominees, which are specified in the Nominating Committee Charter, generally provide that persons to be nominated:
| ● | should have demonstrated notable
or significant achievements in business, education or public service; |
| ● | should possess the requisite intelligence,
education and experience to make a significant contribution to the board of directors and
bring a range of skills, diverse perspectives and backgrounds to its deliberations; and |
| ● | should have the highest ethical standards,
a strong sense of professionalism and intense dedication to serving the interests of the
stockholders. |
The Nominating Committee will
consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism in
evaluating a person’s candidacy for membership on the board of directors. The nominating committee may require certain skills or
attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider
the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating committee does not
distinguish among nominees recommended by stockholders and other persons.
Compensation Committee Interlocks and Insider
Participation
None of our officers currently
serves, and in the past year has not served, (i) as a member of the compensation committee or Board of Directors of another entity,
one of whose executive officers served on our compensation committee, or (ii) as a member of the compensation committee of another
entity, one of whose executive officers served on our Board of Directors.
Code of Ethics
We have adopted a Code of Ethics
applicable to our directors, officers and employees. We have filed a copy of our form of Code of Ethics and our audit committee, Compensation
Committee and nominating Committee Charters as exhibits to this report. You will be able to review these documents by accessing our public
filings at the SEC’s web site at www.sec.gov. In addition, a copy of the Code of Ethics will be provided without charge
upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report
on Form 8-K.
Conflicts of Interest
Each of our directors and officers
presently has, and in the future any of our directors and our officers may have additional, fiduciary or contractual obligations to other
entities pursuant to which such officer or director is or will be required to present acquisition opportunities to such entity. Accordingly,
subject to his or her fiduciary duties under Delaware law, if any of our officers or directors becomes aware of an acquisition opportunity
which is suitable for an entity to which he or she has then current fiduciary or contractual obligations, he or she will need to honor
his or her fiduciary or contractual obligations to present such acquisition opportunity to such entity, and only present it to us if
such entity rejects the opportunity. Our amended and restated certificate of incorporation provides that, subject to his or her fiduciary
duties under Delaware law, we renounce our interest in any corporate opportunity offered to any officer or director unless such opportunity
is expressly offered to such person solely in his or her capacity as a director or officer of our company and such opportunity is one
we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue. We do not believe, however,
that any fiduciary duties or contractual obligations of our directors or officers would materially undermine our ability to complete
our business combination.
Potential investors should
also be aware of the following other potential conflicts of interest:
| ● | None of our officers or directors
is required to commit his or her full time to our affairs and, accordingly, may have conflicts
of interest in allocating his or her time among various business activities. |
| ● | In the course of their other business
activities, our officers and directors may become aware of investment and business opportunities
which may be appropriate for presentation to us as well as the other entities with which
they are affiliated. Our management may have conflicts of interest in determining to which
entity a particular business opportunity should be presented. |
| ● | Our sponsor, officers and directors have agreed to waive their redemption
rights with respect to our founder shares, private placement shares and public shares in connection with the consummation of our initial
business combination. Additionally, our sponsor, officers and directors have agreed to waive their redemption rights with respect to their
founder shares and private placement shares if we fail to consummate our initial business combination within 9 months from the closing
of the IPO (or up to 21 months from the closing of the IPO if we extend the period of time to consummate a business combination,
as described in more detail herein). If we do not complete our initial business combination within such applicable time period, the proceeds
of the sale of the private placement units held in the trust account will be used to fund the redemption of our public shares, and the
private placement units and underlying securities will be worthless. With certain limited exceptions, 50% of the founder shares will not
be transferable, assignable or salable by our sponsor until the earlier of (i) six months after the date of the consummation
of our initial business combination or (ii) the date on which the closing price of our shares of common stock equals or exceeds $12.50
per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any
30-trading day period commencing after our initial business combination and the remaining 50% of the founder shares may not be transferred,
assigned or sold until six months after the date of the consummation of our initial business combination, or earlier, in either case,
if, subsequent to our initial business combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction
which results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property.
With certain limited exceptions, the private placement units and underlying securities will not be transferable, assignable or salable
by our sponsor until 30 days after the completion of our initial business combination. Since our sponsor and officers and directors
may directly or indirectly own shares of common stock, rights and warrants following the IPO, our officers and directors may have a conflict
of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business
combination. |
| ● | Our officers and directors may have
a conflict of interest with respect to evaluating a particular business combination if the
retention or resignation of any such officers and directors was included by a target business
as a condition to any agreement with respect to our initial business combination. |
The conflicts described above
may not be resolved in our favor.
Accordingly, as a result of
multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities
meeting the above-listed criteria to multiple entities. Below is a table summarizing the entities to which our officers and directors
currently have fiduciary duties or contractual obligations:
Name
of Individual |
|
Entity |
|
Entity’s
Business |
|
Affiliation |
Jonathan P. Myers |
|
Ventac Partners |
|
Consulting |
|
Partner |
Hao Shen |
|
NCH Huayang |
|
Industry Solutions |
|
Director |
|
|
Shanghai Zhaohui Network
Technology Co., Ltd |
|
IT Solutions |
|
Founder & Managing
Director |
|
|
Renrui HR |
|
HR Solutions |
|
Director |
Jialuan Ma |
|
— |
|
— |
|
— |
Yong Seog Jung |
|
Hochang Business Consulting
Co., Ltd |
|
Consulting |
|
CEO |
Lin Shi |
|
Beijing Tiantan Hospital |
|
Medical Hospital |
|
Associate Senior Neurosurgeon |
Accordingly, if any of the
above officers or directors become aware of a business combination opportunity which is suitable for any of the above entities to which
he or she has then-current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations
to present such business combination opportunity to such entity, and only present it to us if such entity rejects the opportunity, subject
to his or her fiduciary duties under Delaware law. We do not believe, however, that any of the foregoing fiduciary duties or contractual
obligations will materially affect our ability to complete our initial business combination, because the specific focuses of a majority
of these entities differ from our focus and the type or size of the transaction that such companies would most likely consider are of
a size and nature substantially different than what we are targeting.
We are not prohibited from
pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors. In the event we seek
to complete our initial business combination with such a company, we, or a committee of independent directors, would obtain an opinion
from an independent investment banking firm or another independent firm that commonly renders valuation opinions for the type of company
we are seeking to acquire or an independent accounting firm, that such an initial business combination is fair to our company from a
financial point of view.
In the event that we submit
our initial business combination to our public stockholders for a vote, our sponsor, officers and directors have agreed, pursuant to
the terms of a letter agreement entered into with us, to vote any founder shares and private placement shares held by them (and their
permitted transferees will agree) and any public shares purchased during or after our initial public offering in favor of our initial
business combination.
Section 16(a) Beneficial
Ownership Reporting Compliance
Section 16(a) of
the Exchange Act requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of our
equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our shares of Common
Stock and other equity securities. These executive officers, directors, and greater than 10% beneficial owners are required by SEC regulation
to furnish us with copies of all Section 16(a) forms filed by such reporting persons.
Based solely on our review
of such forms furnished to us and written representations from certain reporting persons, we are not aware of any late Section 16(a) filings
by our executive officers, directors and greater than 10% beneficial owners during the year ended December 31, 2022, except for one late
Form 3 report filed by each of Jonathan P. Myers, Hao Shen, Jialuan Ma, Lin Shi, Yong Seog Jung, Guojian Zhang and Qomolangma Investments
LLC.
Item
11. Executive Compensation.
Employment Agreements
We have not entered
into any employment agreements with our executive officers and have not made any agreements to provide benefits upon termination of employment.
Executive Officers
and Director Compensation
No executive officer
has received any cash compensation for services rendered to us and no compensation of any kind, including finders, consulting or other
similar fees, will be paid to any of our existing stockholders, including our directors, or any of their respective affiliates, prior
to, or for any services they render in order to effectuate, the consummation of a business combination. However, such individuals will
be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target
businesses and performing due diligence on suitable business combinations. There is no limit on the amount of these out-of-pocket expenses
and there will be no review of the reasonableness of the expenses by anyone other than our board of directors and Audit Committee, which
includes persons who may seek reimbursement, or a court of competent jurisdiction if such reimbursement is challenged.
Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The following table sets
forth as of March 31, 2023 the number of shares of Common Stock beneficially owned by (i) each person who is known by us to be the
beneficial owner of more than five percent of our issued and outstanding shares of Common Stock (ii) each of our officers and directors;
and (iii) all of our officers and directors as a group. As of March 31, 2023, we had 6,935,623 shares of Common Stock issued and
outstanding.
Unless otherwise indicated, we believe that all persons named in the
table have sole voting and investment power with respect to all shares of Common Stock beneficially owned by them. The following
table does not reflect record of beneficial ownership of any shares of Common Stock issuable upon exercise of the Warrants or the Rights,
as the Warrants and the Rights are not convertible within 60 days of March 31, 2023.
Name and Address of Beneficial Owner(1) | |
Amount and
Nature of
Beneficial
Ownership | | |
Approximate
Percentage of
Outstanding
Shares of
Common Stock | |
Qomolangma Investments LLC(2) | |
| 1,410,500 | | |
| 21.50 | % |
Jonathan Myers | |
| 20,000 | | |
| * | % |
Hao Shen | |
| 15,000 | | |
| * | % |
Jialuan Ma | |
| 15,000 | | |
| * | % |
Yong Seog Jung | |
| 12,500 | | |
| * | % |
Lin Shi | |
| 12,500 | | |
| * | % |
All directors and officers as a group (5 individuals) | |
| 75,000 | | |
| 1.14 | % |
(1) | Unless otherwise indicated, the business address of each
of the individuals is 1178 Broadway, 3rd Floor, New York, NY 10001. |
(2) | Our sponsor is the record holder of such shares. The address
for our sponsor is 1178 Broadway, 3rd Floor, New York, NY 10001. Guojian Zhang exercises voting and investment
control over the securities held by our sponsor. Mr. Zhang is a resident of China. |
Transfers of Founder Shares and Private
Placement Units
The founder shares, private
placement units and any underlying securities are each subject to transfer restrictions pursuant to lock-up provisions in the letter
agreement with us entered into by our sponsor. Those lock-up provisions provide that such securities are not transferable or salable
(i) in the case of (A) 50% of the founder shares, until the earlier of (x) six months after the date of the consummation
of our initial business combination or (z) the date on which the closing price of our shares of common stock equals or exceeds $12.50
per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within
any 30-trading day period commencing after our initial business combination and (B) the remaining 50% of the founder shares
may not be transferred, assigned or sold until six months after the date of the consummation of our initial business combination,
or earlier, in either case, if, subsequent to our initial business combination, we consummate a subsequent liquidation, merger, stock
exchange or other similar transaction which results in all of our stockholders having the right to exchange their shares of common stock
for cash, securities or other property, and (ii) in the case of the private placement units and the underlying securities, until
30 days after the completion of our initial business combination, except in each case (a) to our sponsor’s officers or
directors, any affiliates or family members of our sponsor or any of our officers or directors, any members of our sponsor, or any affiliates
of our sponsor, (b) in the case of an individual, by gift to a member of the individual’s immediate family or to a trust,
the beneficiary of which is a member of the individual’s immediate family or an affiliate of such person, or to a charitable organization;
(c) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual; (d) in the case
of an individual, pursuant to a qualified domestic relations order; (e) in the event of our liquidation prior to our completion
of our initial business combination; or (f) by virtue of the laws of the State of Delaware or our sponsor’s organizational
or governing documents upon dissolution of our sponsor; provided, however, that in the case of clauses (a) through (f) these
permitted transferees must enter into a written agreement agreeing to be bound by these transfer restrictions and by the same agreements
entered into by our sponsor with respect to such securities (including provisions relating to voting, the trust account and liquidation
distributions described elsewhere in this report).
Registration Rights
The holders of the founder
shares, private placement units, and units that may be issued on conversion of working capital loans (and any securities underlying the
private placement units and the working capital loans) are entitled to registration rights pursuant to a registration rights agreement
signed on the effective date of the IPO requiring us to register such securities for resale. The holders of these securities are entitled
to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back”
registration rights with respect to registration statements filed subsequent to our completion of our initial business combination and
rights to require us to register for resale such securities pursuant to Rule 415 under the Securities Act. We will bear the expenses
incurred in connection with the filing of any such registration statements.
Item
13. Certain Relationships and Related Party Transactions
On September 25, 2021, we issued 1,437,500 shares of common stock
or founder shares to our sponsor for an aggregate purchase price of $25,000, or approximately $0.0174 per share. Of the 1,437,500 founder
shares that were issued and outstanding, up to 187,500 shares were subject to forfeiture by the sponsor to the extent that the underwriters’
over-allotment is not exercised in full, so that the sponsor would collectively own 20% of our issued and outstanding shares after the
IPO (assuming the sponsor did not purchase any Public Units in the IPO and excluding the Private Units). As a result of the underwriters’
partial exercise of their over-allotment option on October 4, 2022, 119,250 founder shares were forfeited for no consideration on October
7, 2022 resulting in 1,318,250 founder shares outstanding after the forfeiture.
On October 4, 2022, simultaneously
with the closing of the IPO, our sponsor purchased an aggregate of 260,500 private placement units at a price of $10.00 per Private Unit
for an aggregate purchase price of $2,605,000. Simultaneously with the closing of the over-allotment option, we issued an additional
8,873 Private Units to the sponsor at a price of $10.00 per Private Unit, generating total proceeds of $88,725. Each Private Unit consists
of one private placement share, one private placement right granting the holder thereof the right to receive one-tenth (1/10) of a share
of common stock upon the consummation of an initial business combination, and one private placement warrant. Each private placement warrant
entitles the holder upon exercise to purchase one share of common stock at a price of $11.50 per share, subject to adjustment as provided
herein. The Private Units (including the underlying securities) may not, subject to certain limited exceptions, be transferred, assigned
or sold by it until 30 days after the completion of our initial business combination.
If any of our officers or directors
becomes aware of a business combination opportunity that falls within the line of business of any entity to which he or she has then-current
fiduciary or contractual obligations, he or she may be required to present such business combination opportunity to such entity prior
to presenting such business combination opportunity to us, subject to his or her fiduciary duties under Delaware law. Our officers and
directors currently have certain relevant fiduciary duties or contractual obligations that may take priority over their duties to us.
We entered into an Administrative
Services Agreement with our sponsor, pursuant to which we will pay a total of $10,000 per month for office space, administrative and
support services. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees. Accordingly,
in the event the consummation of our initial business combination takes the maximum 21 months, our sponsor will be paid a total
of $210,000 ($10,000 per month) for office space, administrative and support services and will be entitled to be reimbursed for any out-of-pocket
expenses.
Our sponsor, officers and directors,
or any of their respective affiliates, will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our
behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee
will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates and will
determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of out-of-pocket
expenses incurred by such persons in connection with activities on our behalf.
On September 5, 2021, our sponsor
agreed to loan us up to $200,000 to be used for a portion of the expenses of the IPO. As of September 30, 2022, $200,000 was outstanding
under the promissory note with our sponsor. We repaid the outstanding balance of $200,000 to our sponsor on October 7, 2022.
In addition, in order to finance
transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or certain
of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete an initial business combination,
we would repay such loaned amounts. In the event that the initial business combination does not close, we may use a portion of the working
capital held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment.
Up to $1,500,000 of such loans may be convertible into units at a price of $10.00 per unit (which, for example, would result in the holders
being issued 165,000 shares of common stock if $1,500,000 of notes were so converted (including 15,000 shares upon the closing of our
initial business combination in respect of 150,000 rights included in such units), as well as 150,000 warrants to purchase 150,000
shares) at the option of the lender. The units would be identical to the private placement units issued to our sponsor. The terms of
such loans by our sponsor, affiliate of our sponsor, or certain of our officers and directors, if any, have not been determined and no
written agreements exist with respect to such loans. We do not expect to seek loans from parties other than our sponsor or an affiliate
of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights
to seek access to funds in our trust account.
After our initial business
combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company
with any and all amounts being fully disclosed to our stockholders, to the extent then known, in the tender offer or proxy solicitation
materials, as applicable, furnished to our stockholders. It is unlikely the amount of such compensation will be known at the time of
distribution of such tender offer materials or at the time of a stockholder meeting held to consider our initial business combination,
as applicable, as it will be up to the directors of the post-combination business to determine executive and director compensation.
We have entered into a registration
rights agreement with respect to the founder shares, private placement units and units issued upon conversion of working capital loans
(if any), and the securities underlying the private placement units and the working capital loans (if any).
Related Party Policy
Our code of ethics requires
us to avoid, wherever possible, all conflicts of interests, except under guidelines or resolutions approved by our Board of Directors
(or the audit committee). Under our code of ethics, conflict of interest situations will include any financial transaction, arrangement
or relationship (including any indebtedness or guarantee of indebtedness) involving us.
Our audit committee, pursuant
to a written charter, will be responsible for reviewing and approving related party transactions to the extent that we enter into such
transactions. An affirmative vote of a majority of the members of the audit committee present at a meeting at which a quorum is present
will be required in order to approve a related party transaction. A majority of the members of the entire audit committee will constitute
a quorum. Without a meeting, the unanimous written consent of all of the members of the audit committee will be required to approve a
related party transaction. We also require each of our directors and executive officers to complete a directors’ and officers’
questionnaire that elicits information about related party transactions.
These procedures are intended
to determine whether any such related party transaction impairs the independence of a director or presents a conflict of interest on
the part of a director, employee or officer.
To further minimize conflicts
of interest, we have agreed not to consummate an initial business combination with an entity that is affiliated with any of our sponsor,
officers or directors unless we, or a committee of independent directors, have obtained an opinion from an independent investment banking
firm or another independent firm that commonly renders valuation opinions for the type of company we are seeking to acquire or an independent
accounting firm, that our initial business combination is fair to our company from a financial point of view. Furthermore, no finder’s
fees, reimbursements or cash payments will be made to our sponsor, officers or directors, or our or their affiliates, for services rendered
to us prior to or in connection with the completion of our initial business combination.
Our audit committee will review
on a quarterly basis all payments that were made to our sponsor, officers or directors, or our or their affiliates.
Nasdaq listing standards
require that a majority of our board of directors be independent. For a description of the director independence, see above Part III,
Item 10 – Directors, Executive Officers and Corporate Governance.
Item 14.
Principal Accountant Fees and Services
The following is a summary
of fees paid or to be paid to Marcum LLP (“Marcum”) and Friedman LLP (“Friedman”), prior to the acquisition of
certain assets of Friedman by Marcum effective September 1, 2022, for services rendered.
Audit Fees. Audit fees consist of fees billed for professional services rendered
for the audit of our year-end financial statements and services that are normally provided by Friedman and Marcum in connection with regulatory
filings. The aggregate fees billed by Friedman and Marcum for professional services rendered for the audit of our annual financial statements,
review of the financial information included in our Forms 10-Q for the respective periods and other required filings with the SEC for
the year ended December 31, 2022 and for the period from May 6, 2021 (inception) through December 31, 2021 totaled $87,750 and $25,000,
respectively. The above amounts include interim procedures and audit fees, as well as attendance at audit committee meetings and professional
services rendered in connection with the IPO.
Audit-Related Fees.
Audit-related services consist of fees billed for assurance and related services that are reasonably related to performance of the audit
or review of our financial statements and are not reported under “Audit Fees.” These services include attest services that
are not required by statute or regulation and consultations concerning financial accounting and reporting standards. We did not pay Marcum
for consultations concerning financial accounting and reporting standards for the year ended December 31, 2022 and for the period from
May 6, 2021 (inception) through December 31, 2021.
Tax Fees. We did
not pay Friedman or Marcum for tax return services, planning and tax advice for the year ended December 31, 2022 and for the period from
May 6, 2021 (inception) through December 31, 2021.
All Other Fees.
We did not pay Friedman or Marcum for other services for the year ended December 31, 2022 and for the period from May 6, 2021 (inception)
through December 31, 2022.
Pre-Approval Policy
Our Audit Committee
was formed upon the consummation of our IPO. As a result, the Audit Committee did not pre-approve all of the foregoing services, although
any services rendered prior to the formation of our Audit Committee were approved by our board of directors. Since the formation of our
Audit Committee, and on a going-forward basis, the Audit Committee has and will pre-approve all auditing services and permitted non-audit
services to be performed for us by our auditors, including the fees and terms thereof (subject to the de minimis exceptions for non-audit
services described in the Exchange Act which are approved by the Audit Committee prior to the completion of the audit).
PART IV
Item 15.
Exhibits, Financial Statement Schedules
| (a) | The following documents are filed as part of this Annual
Report: |
We hereby file as part of this Annual Report
the exhibits listed in the attached Exhibit Index.
Exhibit No. |
|
Description |
4.3 |
|
Specimen Warrant Certificate(incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.4 |
|
Specimen Right Certificate (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.5 |
|
Form of Warrant Agreement between American Stock Transfer & Trust Company, LLC and the Registrant (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.6 |
|
Form of Rights Agreement between American Stock Transfer & Trust Company, LLC and the Registrant (incorporated by reference to Exhibit 4.6 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
4.7* |
|
Description of Registrant’s Securities. |
5.1 |
|
Opinion of Kramer Levin Naftalis & Frankel LLP, counsel to the Registrant (incorporated by reference to Exhibit 5.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.1 |
|
Promissory Note, dated as of September 5, 2021 issued to Qomolangma Investments LLC (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.2 |
|
Form of Letter Agreement among the Registrant, and its officers, directors and Qomolangma Investments LLC (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.3 |
|
Form of Investment Management Trust Agreement between American Stock Transfer & Trust Company, LLC and the Registrant (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.4 |
|
Form of Registration Rights Agreement between the Registrant and certain security holders (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.5 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Qomolangma Investments LLC (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.6 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Jonathan Myers (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.7 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Hao Shen (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.8 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Jialuan Ma (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.9 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Yong Seog Jung (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.10 |
|
Subscription Agreement, dated September 25, 2021 between the Registrant and Lin Shi (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.11 |
|
Private Placement Units Purchase Agreement between the Registrant and Qomolangma Investments LLC (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
Exhibit No. |
|
Description |
10.12 |
|
Form of Indemnity Agreement (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
10.13 |
|
Form of Administrative Services Agreement, by and between the Registrant and Qomolangma Investments LLC (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
14 |
|
Form of Code of Ethics (incorporated by reference to Exhibit 14 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
23.1 |
|
Consent of Friedman LLP (incorporated by reference to Exhibit 23.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
23.2 |
|
Consent of Kramer Levin Naftalis & Frankel LLP (included on Exhibit 5.1) (incorporated by reference to Exhibit 23.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
31.1* |
|
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2* |
|
Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1** |
|
Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2** |
|
Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
99.1 |
|
Form of Audit Committee Charter (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
99.2 |
|
Form of Compensation Committee Charter (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
99.3 |
|
Form of Nominating Committee Charter (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on September 26, 2022). |
101.INS |
|
Inline XBRL Instance Document. |
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document. |
101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document. |
101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document. |
101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
Item
16. Form 10-K Summary
Not Applicable.
SIGNATURES
Pursuant to the requirements of Section 13
or 15(d) of the Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
Qomolangma Acquisition Corp. |
|
|
|
|
By: |
/s/ Jonathan P. Myers |
|
Name: |
Jonathan P. Myers |
|
Title: |
Chief Executive Officer |
|
|
|
Dated: April 7, 2023 |
|
|
Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in
the capacities and on the dates indicated.
Pursuant to the requirements
of the Securities Act of 1933, this report has been signed below by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Jonathan P. Myers |
|
|
|
|
Jonathan P. Myers |
|
Chief Executive Officer, President and Director |
|
April 7, 2023 |
|
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Hao Shen |
|
|
|
|
Hao Shen |
|
Chief Financial Officer |
|
April 7, 2023 |
|
|
(Principal Accounting and Financial Officer) |
|
|
|
|
|
|
|
/s/ Jialuan Ma |
|
|
|
|
Jialuan Ma |
|
Director |
|
April 7, 2023 |
|
|
|
|
|
/s/ Yong Seog Jung |
|
|
|
|
Yong Seog Jung |
|
Director |
|
April 7, 2023 |
|
|
|
|
|
/s/ Lin Shi |
|
|
|
|
Lin Shi |
|
Director |
|
April 7, 2023 |
QOMOLANGMA ACQUISITION CORP.
INDEX TO FINANCIAL STATEMENTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
To the Stockholders and Board of Directors of
Qomolangma Acquisition Corp.
Opinion on the Financial Statements
We have audited the accompanying balance sheet
of Qomolangma Acquisition Corp. (the “Company”) as of December 31, 2022, the related statements of operations, changes in
stockholders’ equity and cash flows for the year ended December 31, 2022, and the related notes (collectively referred to as the
“financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year ended December 31,
2022, in conformity with accounting principles generally accepted in the United States of America.
Explanatory Paragraph – Going Concern
The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a
significant working capital deficiency and needs to raise additional funds to meet its obligations and sustain its operations. If
the Company does not complete a business combination by July 4, 2023 (or July 4, 2024, if the Company extends the period of time to
complete a business combination), it will be required to cease all operations, except for the purpose of winding up. These
conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these
matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of
this uncertainty.
Basis for Opinion
These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
/s/ Marcum llp
Marcum llp
We have served as the Company’s auditor
since 2021 (such date takes into account the acquisition of certain assets of Friedman LLP by Marcum LLP effective September 1, 2022).
Costa Mesa, CA
April 7, 2023
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
To the Board of Directors and Stockholders of
Qomolangma Acquisition Corp.
Opinion on the Financial Statements
We have audited the accompanying balance sheet
of Qomolangma Acquisition Corp. (the “Company”) as of December 31, 2021 and the related statements of operations, changes
in stockholders’ equity and cash flows for the period from May 6, 2021 (inception) through December 31, 2021 and the related notes
(collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all
material respects, the financial position of the Company as of December 31, 2021 and the results of its operations and its cash flows
for the period from May 6, 2021 (inception date) through December 31, 2021, in conformity with accounting principles generally accepted
in the United States of America.
Explanatory Paragraph — Going Concern
The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, its business
plan is dependent on the completion of a financing and the Company’s cash and working capital as of December 31, 2021 are not sufficient
to complete its planned activities. These conditions raise substantial doubt about the Company’s ability to continue as a going
concern. Management’s plans in regard to these matters are also described in Notes 1 and 3. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
/s/ Friedman LLP
Friedman LLP
We served as the Company’s auditor from
2021 through 2022.
New York, NY
March 22, 2022
QOMOLANGMA ACQUISITION CORP.
BALANCE SHEETS
| |
December 31, 2022 | | |
December 31, 2021 | |
Assets | |
| | |
| |
Current Assets | |
| | |
| |
Cash | |
$ | 196,510 | | |
$ | 154,565 | |
Prepaid expenses | |
| 235,476 | | |
| — | |
Total Current Assets | |
| 431,986 | | |
| 154,565 | |
| |
| | | |
| | |
Deferred offering costs | |
| — | | |
| 133,000 | |
Investments held in Trust Account | |
| 53,958,681 | | |
| — | |
Total Assets | |
$ | 54,390,667 | | |
$ | 287,565 | |
| |
| | | |
| | |
Liabilities, Temporary Equity, and Stockholders’ Equity | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accrued expenses | |
$ | 124,599 | | |
$ | 65,000 | |
Franchise tax payable | |
| 45,428 | | |
| — | |
Income tax payable | |
| 46,115 | | |
| — | |
Due to related party | |
| — | | |
| 1,500 | |
Promissory note - related party | |
| 155,025 | | |
| 200,000 | |
Total Current Liabilities | |
| 371,167 | | |
| 266,500 | |
| |
| | | |
| | |
Deferred tax liability | |
| 36,164 | | |
| — | |
Deferred underwriting fee payable | |
| 2,109,200 | | |
| — | |
Total Liabilities | |
| 2,516,531 | | |
| 266,500 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| | | |
| | |
| |
| | | |
| | |
Common stock subject to possible redemption, $0.0001 par value; 16,000,000 shares authorized; 5,273,000 shares issued and outstanding at redemption value | |
| 46,828,833 | | |
| — | |
| |
| | | |
| | |
Stockholders’ Equity | |
| | | |
| | |
Common stock, $0.0001 par value; 16,000,000 shares authorized; 1,662,623 (excluding 5,273,000 shares subject to possible redemption) and 1,437,500 shares issued and outstanding at December 31, 2022 and December 31, 20211, respectively | |
| 166 | | |
| 144 | |
Additional paid-in capital | |
| 4,914,221 | | |
| 24,856 | |
Retained earnings (Accumulated deficit) | |
| 130,916 | | |
| (3,935 | ) |
Total Stockholders’ Equity | |
| 5,045,303 | | |
| 21,065 | |
Total Liabilities, Temporary Equity, and Stockholders’ Equity | |
$ | 54,390,667 | | |
$ | 287,565 | |
1 | Includes up to 187,500 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part (see Note 5). On October 4, 2022, the underwriters partially exercised the over-allotment option resulting in forfeiture of 119,250 shares of common stock. |
The accompanying notes are an integral part of
these financial statements.
QOMOLANGMA
ACQUISITION CORP.
STATEMENTS OF OPERATIONS
| |
For the year
ended
December 31, | | |
For the
period from
May 6, 2021
(inception)
through
December 31, | |
| |
2022 | | |
2021 | |
| |
| | |
| |
General and administrative expenses | |
$ | 174,673 | | |
$ | 3,935 | |
Franchise tax expenses | |
| 45,928 | | |
| — | |
Loss from operations | |
| (220,601 | ) | |
| (3,935 | ) |
| |
| | | |
| | |
Interest earned on investments held in Trust Account | |
| 437,731 | | |
| — | |
Income (loss) before income taxes | |
| 217,130 | | |
| (3,935 | ) |
| |
| | | |
| | |
Income taxes provision | |
| (82,279 | ) | |
| — | |
Net income (loss) | |
$ | 134,851 | | |
$ | (3,935 | ) |
| |
| | | |
| | |
Basic and diluted weighted average shares outstanding, redeemable common stock | |
| 1,269,055 | | |
| — | |
| |
| | | |
| | |
Basic and diluted net income per share, redeemable common stock | |
| 1.46 | | |
| — | |
| |
| | | |
| | |
Basic and diluted weighted average shares outstanding, non-redeemable common stock | |
| 1,401,204 | | |
| 1,250,000 | (1) |
| |
| | | |
| | |
Basic and diluted net loss per share, non-redeemable common stock | |
$ | (1.23 | ) | |
$ | (0.00 | ) |
1 | Excludes up to 187,500 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part (see Note 5). On October 4, 2022, the underwriters partially exercised the over-allotment option resulting in forfeiture of 119,250 shares of common stock. |
The accompanying notes are an integral part of
these financial statements.
QOMOLANGMA
ACQUISITION CORP.
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
For the year ended December 31,
2022
| |
Common stock | | |
Additional Paid-in | | |
Retained Earnings (Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit) | | |
Equity | |
Balance as of January 1, 2022 | |
| 1,437,500 | | |
$ | 144 | | |
$ | 24,856 | | |
$ | (3,935 | ) | |
$ | 21,065 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Sale of public units in initial public offering | |
| 5,273,000 | | |
| 527 | | |
| 52,729,473 | | |
| — | | |
| 52,730,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Sale of private placement units | |
| 269,373 | | |
| 27 | | |
| 2,693,698 | | |
| — | | |
| 2,693,725 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Forfeiture of founder shares | |
| (119,250 | ) | |
| (12 | ) | |
| 12 | | |
| — | | |
| — | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of representative shares | |
| 75,000 | | |
| 7 | | |
| 673,493 | | |
| — | | |
| 673,500 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Underwriter commissions | |
| — | | |
| — | | |
| (3,031,975 | ) | |
| — | | |
| (3,031,975 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Offering costs | |
| — | | |
| — | | |
| (1,347,030 | ) | |
| — | | |
| (1,347,030 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Reclassification of common stock subject to redemption | |
| (5,273,000 | ) | |
| (527 | ) | |
| (43,418,666 | ) | |
| — | | |
| (43,419,193 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Accretion of common stock to redemption value | |
| — | | |
| — | | |
| (3,409,640 | ) | |
| — | | |
| (3,409,640 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net income | |
| — | | |
| — | | |
| — | | |
| 134,851 | | |
| 134,851 | |
Balance as of December 31, 2022 | |
| 1,662,623 | | |
$ | 166 | | |
$ | 4,914,221 | | |
$ | 130,916 | | |
$ | 5,045,303 | |
For the period from May 6, 2021 (inception) through December
31, 2021
| |
Common Stock | | |
Additional Paid-In | | |
Accumulated | | |
Total Stockholder’s | |
| |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Equity | |
Balance as of May 6, 2021 (inception) | |
| — | | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | — | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of founder shares1 | |
| 1,437,500 | | |
| 144 | | |
| 24,856 | | |
| — | | |
| 25,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss | |
| — | | |
| — | | |
| — | | |
| (3,935 | ) | |
| (3,935 | ) |
Balance as of December 31, 2021 | |
| 1,437,500 | | |
$ | 144 | | |
$ | 24,856 | | |
$ | (3,935 | ) | |
$ | 21,065 | |
1 | Includes up to 187,500 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part (see Note 5). On October 4, 2022, the underwriters partially exercised the over-allotment option resulting in forfeiture of 119,250 shares of common stock. |
The accompanying notes are an integral part of
these financial statements.
QOMOLANGMA
ACQUISITION CORP.
STATEMENTS OF CASH FLOWS
| |
For the year
ended
December 31,
2022 | | |
For the
period from
May 6, 2021
(inception)
through
December 31,
2021 | |
Cash flows from operating activities: | |
| | |
| |
Net income (loss) | |
$ | 134,851 | | |
$ | (3,935 | ) |
Adjustments to reconcile net cash used in operating activities: | |
| | | |
| | |
Interest earned on investments held in Trust Account | |
| (437,731 | ) | |
| — | |
Deferred tax | |
| 36,164 | | |
| — | |
Changes in current assets and current liabilities: | |
| | | |
| | |
Prepaid expenses | |
| (235,476 | ) | |
| — | |
Accrued expenses | |
| 59,599 | | |
| — | |
Franchise tax payable | |
| 45,428 | | |
| — | |
Income tax payable | |
| 46,115 | | |
| — | |
Net cash used in operating activities | |
| (351,050 | ) | |
| (3,935 | ) |
| |
| | | |
| | |
Cash Flows from Investing Activities: | |
| | | |
| | |
Purchase of investments held in Trust Account | |
| (53,520,950 | ) | |
| — | |
Net cash used in investing activities | |
| (53,520,950 | ) | |
| — | |
| |
| | | |
| | |
Cash Flows from Financing Activities: | |
| | | |
| | |
Proceeds from issuance of founder shares to the initial stockholders | |
| — | | |
| 25,000 | |
Proceeds from sale of public units through public offering | |
| 52,730,000 | | |
| — | |
Proceeds from sale of private placement units | |
| 2,693,725 | | |
| — | |
Advance from related party | |
| — | | |
| 1,500 | |
Proceeds from issuance of promissory note to related party | |
| 153,525 | | |
| 200,000 | |
Repayment of promissory note to related party | |
| (200,000 | ) | |
| — | |
Payment of underwriters’ commissions | |
| (922,775 | ) | |
| — | |
Payment of deferred offering costs | |
| (540,530 | ) | |
| (68,000 | ) |
Net cash provided by financing activities | |
| 53,913,945 | | |
| 158,500 | |
| |
| | | |
| | |
Net change in cash | |
| 41,945 | | |
| 154,565 | |
Cash, beginning of the period | |
| 154,565 | | |
| — | |
Cash, end of the period | |
$ | 196,510 | | |
$ | 154,565 | |
Supplemental Disclosure of Non-cash Investing and Financing Activities | |
| | | |
| | |
Initial classification of common stock subject to redemption | |
$ | 43,419,193 | | |
$ | — | |
Deferred underwriting fee payable | |
$ | 2,109,200 | | |
$ | — | |
Accretion of Common stock to redemption value | |
$ | 3,409,640 | | |
$ | — | |
Public offering costs included in accrued expenses | |
$ | — | | |
$ | 65,000 | |
Interest paid | |
$ | — | | |
$ | — | |
Income tax paid | |
$ | — | | |
$ | — | |
The accompanying notes are an integral part of
these financial statements.
QOMOLANGMA ACQUISITION CORP.
NOTES TO FINANCIAL STATEMENTS
Note 1 — Description of Organization and Business
Operations
Qomolangma Acquisition Corp. (the “Company”)
is a newly organized blank check company incorporated as a Delaware corporation on May 6, 2021. The Company was formed for the purpose
of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more
businesses or entities (“Business Combination”). The Company intends to pursue target businesses that are strategically significant
in the Asian markets and focus on businesses with a total enterprise value of between $300,000,000 and $500,000,000.
As of December 31, 2022, the Company had not commenced any operations.
All activities through December 31, 2022 are related to the Company’s formation and the proposed initial public offering (“IPO”
as defined below) and, subsequent to the IPO, identifying a target company for a Business Combination. The Company will not generate any
operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in
the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.
The Company’s sponsor is Qomolangma Investments
LLC (the “Sponsor”), a Delaware limited liability company.
The registration statement for the Company’s
IPO became effective on September 29, 2022. On October 4, 2022, the Company consummated the IPO of 5,000,000 units at an offering price
of $10.00 per unit (the “Public Units’), generating gross proceeds of $50,000,000. Simultaneously with the closing of the
IPO, the Company sold to the Sponsor, in a private placement, 260,500 units, at $10.00 per unit (the “Private Units”), generating
total gross proceeds of $2,605,000.
Transaction costs from the IPO amounted to $4,222,030,
consisting of $875,000 of underwriting fees, $2,000,000 of deferred underwriting fees (payable only upon completion of a Business Combination)
and $1,347,030 of other offering costs.
The Company granted the underwriter a 45-day option
to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 4, 2022, the underwriter partially exercised
the over-allotment option and purchased 273,000 Public Units at a price of $10.00 per Public Unit on October 7, 2022, generating gross
proceeds of $2,730,000. Simultaneously with the closing of the over-allotment option, the Company consummated the private placement of
an additional 8,873 Private Units generating gross proceeds of $88,725.
A total of $53,520,950 ($10.15 per Unit) of the net proceeds from the
sale of Units in the IPO (including the Over-Allotment Option Units) and the private placements on October 4, 2022 and October 7, 2022,
was placed in a trust account (the “Trust Account”) maintained by American Stock Transfer & Trust Company as a trustee
and are invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds meeting certain conditions
under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”), and that invest only
in direct U.S. government treasury obligations. These funds will not be released until the earlier of the completion of the initial Business
Combination and the liquidation due to the Company’s failure to complete a Business Combination within the applicable period of
time. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could
have priority over the claims of the Company’s public stockholders. In addition, interest income earned on investments held in the
Trust Account may be released to the Company to pay its income or other tax obligations. With these exceptions, expenses incurred by the
Company may be paid prior to a Business Combination only from the net proceeds of the IPO and private placement not held in the Trust
Account.
Pursuant to Nasdaq listing rules, the Company’s
initial Business Combination must occur with one or more target businesses having an aggregate fair market value equal to at least 80%
of the value of the funds in the Trust account (excluding any deferred underwriting discounts and commissions and taxes payable on the
income earned on the Trust Account), which the Company refers to as the 80% test, at the time of the execution of a definitive agreement
for its initial Business Combination, although the Company may structure a Business Combination with one or more target businesses whose
fair market value significantly exceeds 80% of the trust account balance. If the Company is no longer listed on Nasdaq, it will not be
required to satisfy the 80% test. The Company will only complete a Business Combination if the post-transaction company owns or acquires
50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for
it not to be required to register as an investment company under the Investment Company Act.
The Company will provide its holders of the outstanding
Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the
completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or
(ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct
a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public
Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.15 per Public Share, plus any pro
rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income
tax obligations).
The Company will proceed with a Business Combination
if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks
stockholder approval, a majority of the shares of common stock voted are voted in favor of the Business Combination. If a stockholder
vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company
will, pursuant to its Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”),
conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and
file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction
is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem
shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally,
each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction.
If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor and any of the Company’s
officers or directors that may hold Founder Shares (as defined in Note 5) (the “Initial Stockholders”) and the underwriters
have agreed (a) to vote their Founder Shares, Private Shares (as defined in Note 4), and any Public Shares purchased during
or after the IPO in favor of approving a Business Combination and (b) not to convert any shares (including the Founder Shares) in
connection with a stockholder vote to approve, or sell the shares to the Company in any tender offer in connection with, a proposed Business
Combination.
The Initial Stockholders have agreed (a) to
waive their redemption rights with respect to the Founder Shares, Private Shares, and Public Shares held by them in connection with the
completion of a Business Combination and (b) not to propose, or vote in favor of, an amendment to the Amended and Restated Certificate
of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the
Company does not complete a Business Combination, unless the Company provides the Public Stockholders with the opportunity to redeem their
Public Shares in conjunction with any such amendment.
The Company has until July 4, 2023 (or up to July 4, 2024 if the time
to complete a business combination is extended as described herein) to consummate a Business Combination. In addition, if the Company
anticipates that it may not be able to consummate a Business Combination within 9 months, the Company may extend the period of time to
consummate a Business Combination up to twelve times, each by an additional one month (for a total of 21 months to complete a Business
Combination) (the “Combination Period”). In order to extend the time available for the Company to consummate a Business Combination,
the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the applicable deadline,
must deposit into the Trust Account $174,009 ($0.033 per Public Share per month), on or prior to the date of the applicable deadline,
for each extension.
If the Company is unable to complete a Business
Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as
promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest (which interest shall be net of
taxes payable, and less certain amount of interest to pay dissolution expenses) divided by the number of then outstanding Public Shares,
which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further
liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate,
subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of
other applicable law.
The Initial Stockholders have agreed to waive
their liquidation rights with respect to the Founder Shares and Private Shares if the Company fails to complete a Business Combination
within the Combination Period. However, if the Sponsor or underwriters acquires Public Shares in or after the IPO, such Public Shares
will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the
Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held
in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event,
such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public
Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution
will be less than $10.15.
In order to protect the amounts held in the Trust
Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products
sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce
the amount of funds in the Trust Account to below $10.15 per Public Share, except as to any claims by a third party who executed a valid
and enforceable agreement with the Company waiving any right, title, interest or claim of any kind they may have in or to any monies held
in the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event
that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any
liability for such third party claims.
Liquidity, Capital Resources and Going Concern
As of December 31, 2022, the Company had $196,510 of cash held outside
its trust account and a working capital of $152,362 (excluding income tax and franchise tax payable as the taxes are paid out of the Trust
Account). On March 22, 2023, the Sponsor loaned the Company $200,000, to be used, in part, for transaction costs related to the Business
Combination. The Company has until July 4, 2023 (unless the Company extends the time to complete a Business Combination) to consummate
a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time. If a Business
Combination is not consummated by this date, there will be a mandatory liquidation and subsequent dissolution.
The Company expects to continue to incur significant
professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of
a Business Combination. The Company may need to obtain additional financing either to complete its Business Combination or because it
becomes obligated to redeem a significant number of public shares upon consummation of its Business Combination, in which case the Company
may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities
laws, the Company would only complete such financing simultaneously with the completion of our Business Combination. If the Company is
unable to complete its Business Combination because it does not have sufficient funds available, it will be forced to cease operations
and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need
to obtain additional financing in order to meet its obligations.
In connection with the Company’s assessment
of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”)
2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern”, management has determined
that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. In addition, if the Company
is unable to complete a Business Combination within the Combination Period, the Company’s board of directors would proceed to commence
a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate
a Business Combination will be successful within the Combination Period. As a result, management has determined that such additional condition
also raise substantial doubt about the Company’s ability to continue as a going concern. The financial statement does not include
any adjustments that might result from the outcome of this uncertainty.
Risks and Uncertainties
In March 2020, the World Health Organization declared
the outbreak of a novel coronavirus (“COVID-19”) as a pandemic which continues to spread throughout the United States and
the world. As of the date the financial statements were issued, there was considerable uncertainty around the expected duration of this
pandemic. Management continues to evaluate the impact of the COVID-19 pandemic and the Company has concluded that while it is reasonably
possible that COVID-19 could have a negative effect on completing the IPO and subsequently identifying a target company for a Business
Combination, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.
Additionally, as a result of the military action
commenced in February 2022 by the Russian Federation and Belarus in the country of Ukraine and related economic sanctions, the Company’s
ability to consummate a Business Combination, or the operations of a target business with which the Company ultimately consummates a Business
Combination, may be materially and adversely affected. In addition, the Company’s ability to consummate a transaction may be dependent
on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility,
or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this
action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations
and/or ability to consummate a Business Combination are not yet determinable. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
Inflation Reduction Act of 2022
On August 16, 2022, the Inflation Reduction Act
of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise
tax on certain repurchases (including redemptions) of stock by publicly traded domestic (i.e., U.S.) corporations and certain domestic
subsidiaries of publicly traded foreign corporations. The excise tax is imposed on the repurchasing corporation itself, not its shareholders
from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at
the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair
market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition,
certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority
to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The IR Act applies only to
repurchases that occur after December 31, 2022.
Any redemption or other repurchase that occurs
after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether
and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise
would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business
Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE”
or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination
but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury.
In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment
of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business
Combination and in the Company’s ability to complete a Business Combination.
At this time, it has been determined that none
of the IR Act tax provisions have an impact to the Company’s fiscal 2022 tax provision. The Company will continue to monitor for
updates to the Company’s business along with guidance issued with respect to the IR Act to determine whether any adjustments are
needed to the Company’s tax provision in future periods.
Note 2 — Summary of
Significant Accounting Policies
Basis of Presentation
The accompanying financial statements are presented in conformity with
accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and
regulations of the SEC. Accordingly, they include all of the information and footnotes required by U.S. GAAP. In the opinion of management,
all adjustments (consisting of normal accruals) considered for a fair presentation have been included.
Emerging Growth Company
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the
“JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other
public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent
registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that
a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies
but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means
that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth
company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.
Use of Estimates
In preparing these financial statements in conformity
with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting
period.
Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near
term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company had $196,510 and $154,565 in
cash and none in cash equivalents as of December 31, 2022 and December 31, 2021, respectively.
Investments Held in Trust Account
The Company’s portfolio of investments held in the Trust Account
is comprised of investments in money market funds that invest in U.S. government securities. These securities are presented on the balance
sheet at fair value at the end of each reporting period. Earning on investments held in the Trust Account are included in interest earned
on investments held in Trust Account in the accompanying statements of operations. The estimated fair value of investments held in the
Trust Account is determined using available market information.
Offering Costs
The Company complies with the requirements of FASB ASC Topic 340-10-S99-1,
“Other Assets and Deferred Costs – SEC Materials” (“ASC 340-10-S99”) and SEC Staff Accounting Bulletin Topic
5A, “Expenses of Offering”. Total offering costs of $4,222,030 consisting principally of underwriting, legal, accounting and
other expenses that are directly related to the IPO and charged to stockholders’ equity upon the completion of the IPO on October
4, 2022.
Income Taxes
The Company follows the asset and liability method
of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for
the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets
and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation
allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
ASC 740 prescribes a recognition threshold
and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in
a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing
authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were
no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022. The Company is currently not aware
of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is
subject to income tax examinations by major taxing authorities since inception.
The Company has identified the United States
as its only “major” tax jurisdiction.
The Company may be subject to potential examination
by federal and state taxing authorities in the areas of income taxes. These potential examinations may include questioning the timing
and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s
management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Net Income
(Loss) Per Share
The Company complies with accounting and disclosure requirements of
FASB ASC 260, Earnings Per Share. The statements of operations include a presentation of income (loss) per redeemable share and income
(loss) per non-redeemable share following the two-class method of income per share. In order to determine the net income (loss) attributable
to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income (loss) allocable to both
the redeemable shares and non-redeemable shares and the undistributed income (loss) is calculated using the total net loss less any dividends
paid. The Company then allocated the undistributed income (loss) ratably based on the weighted average number of shares outstanding between
the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible
redemption was considered to be dividends paid to the public shareholders. As of December 31, 2022 and 2021, the Company did not have
any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in
the earnings of the Company. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period
presented.
The net income (loss) per share presented in the
statements of operations is based on the following:
| |
For the year ended December 31, 2022 | | |
For the period from May 6, 2021 (inception) to December 31, 2021 | |
Net Income (Loss) | |
$ | 134,851 | | |
$ | (3,935 | ) |
Accretion of common stock to redemption value | |
| (3,409,640 | ) | |
| — | |
Net loss including accretion of common stock to redemption value | |
$ | (3,274,790 | ) | |
$ | (3,935 | ) |
| |
| | |
| | |
For the | |
| |
| | |
| | |
period from | |
| |
| | |
| | |
May 6, 2021 | |
| |
| | |
| | |
(inception) | |
| |
For the year ended | | |
through | |
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
Redeemable shares | | |
Non- redeemable shares | | |
Redeemable shares | | |
Non- redeemable shares | |
Basic and diluted net income (loss) per common stock | |
| | |
| | |
| | |
| |
Numerator: | |
| | |
| | |
| | |
| |
Allocation of net loss | |
$ | (1,504,808 | ) | |
$ | (1,769,982 | ) | |
$ | — | | |
$ | (3,935 | ) |
Accretion of common stock to redemption value | |
| 3,409,640 | | |
| — | | |
| — | | |
| — | |
Allocation of net income (loss) | |
$ | 1,904,832 | | |
$ | (1,769,982 | ) | |
$ | — | | |
$ | (3,935 | ) |
| |
| | | |
| | | |
| | | |
| | |
Denominator: | |
| | | |
| | | |
| | | |
| | |
Basic and diluted weighted average shares outstanding | |
| 1,269,055 | | |
| 1,401,204 | | |
| — | | |
| 1,250,000 | |
Basic and diluted net income (loss) per common stock | |
$ | 1.46 | | |
$ | (1.23 | ) | |
$ | — | | |
$ | (0.00 | ) |
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal
Depository Insurance Coverage of $250,000. As of December 31, 2022, the Company has not experienced losses on these accounts and management
believes the Company is not exposed to significant risks on such accounts.
Fair Value of Financial Instruments
FASB ASC Topic 820 “Fair Value Measurements
and Disclosures” defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between the
buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach,
income approach and cost approach shall be used to measure fair value. FASB ASC Topic 820 establishes a fair value hierarchy for inputs,
which represent the assumptions used by the buyer and seller in pricing the asset or liability. These inputs are further defined as observable
and unobservable inputs. Observable inputs are those that buyer and seller would use in pricing the asset or liability based on market
data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s assumptions about the inputs that
the buyer and seller would use in pricing the asset or liability developed based on the best information available in the circumstances.
The fair value hierarchy is categorized into three
levels based on the inputs as follows:
Level 1 |
Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. |
Level 2 |
Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. |
Level 3 |
Valuations based on inputs that are unobservable and significant to the overall fair value measurement. |
The fair value of the Company’s certain assets and liabilities,
which qualify as financial instruments under ASC Topic 820, “Fair Value Measurements and Disclosures,” approximates the carrying
amounts represented in the consolidated balance sheet. The fair values of cash, other current assets, accrued expenses, and due to sponsor
are estimated to approximate the carrying values as of December 31, 2022 and 2021 due to the short maturities of such instruments. See
Note 8 for the disclosure of the Company’s assets and liabilities that were measured at fair value on a recurring basis.
Warrants
The Company accounts for warrants as either equity-classified or liability-classified
instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting
Standards Board Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and
Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to
ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity
classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the
warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Consequently, the Company
accounts for warrants as equity-classified instruments.
For issued or modified warrants that meet all
of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the
time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required
to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair
value of the warrants are recognized as a non-cash gain or loss on the statements of operations.
Common Stock Subject to Possible Redemption
The Company accounts for its common stock subject
to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock
subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable
common stock (including common stock that feature redemption rights that is either within the control of the holder or subject to redemption
upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other
times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that
are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common
stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section
of the Company’s balance sheets.
The Company has made a policy
election in accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in additional paid-in capital or accumulated
deficit if additional paid-in capital equals to zero, over an expected 9-month period leading up to a Business Combination. As of December
31, 2022, the Company recorded $3,409,640 total accretion of redeemable common stock to redemption value.
At December 31, 2022, the amount of common stock subject to possible
redemption reflected in the balance sheets are reconciled in the following table:
Gross proceeds | |
$ | 52,730,000 | |
Less: | |
| | |
Proceeds allocated to public warrants | |
| (3,532,910 | ) |
Proceeds allocated to public rights | |
| (1,845,550 | ) |
Allocation of offering costs related to redeemable shares | |
| (3,932,347 | ) |
Plus: | |
| | |
Accretion of carrying value to redemption value | |
| 3,409,640 | |
Common stock subject to possible redemption | |
$ | 46,828,833 | |
Recent Accounting Pronouncements
In August 2020, the Financial Accounting
Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with
Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic
815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current
models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the
derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new
standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in
an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the
if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 for the Company and should be applied
on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company is currently
assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.
Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial
statements.
Note 3 — Initial Public
Offering
Pursuant to its IPO on October 4, 2022, the Company
sold 5,000,000 Units at a price of $10.00 per Unit, generating gross proceeds of $50,000,000. The Company granted the underwriters a 45-day
option to purchase up to 750,000 additional Public Units to cover over-allotments, if any. On October 7, 2022, the underwriter partially
exercised the over-allotment option and purchased 273,000 Public Units at a price of $10.00 per Public Unit, generating gross proceeds
of $2,730,000. Each Public Unit consists of one share of common stock (“Public Share”), one right (“Public Right”)
and one redeemable warrant (“Public Warrant”). Each Public Right will convert into one-tenth (1/10) of one share of common
stock upon the consummation of a Business Combination. Each Public Warrant entitles the holder to purchase one share of common stock at
a price of $11.50 per share, subject to adjustment. The Public Warrants will become exercisable on the later of 30 days following the
completion of the Company’s initial Business Combination or 12 months from the closing of the IPO, and will expire five years after
the completion of the Company’s initial Business Combination or earlier upon redemption or liquidation.
All of the 5,273,000 Public Shares sold as part
of the Public Units in the IPO (including over-allotment units) contain a redemption feature which allows for the redemption of such Public
Shares if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments
to the Company’s amended and restated certificate of incorporation, or in connection with the Company’s liquidation. In accordance
with the SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions
not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity.
The Company’s redeemable common stock is
subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable
that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the
period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the
earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying
amount of the instrument to equal the redemption value at the end of each reporting period. The Company has made a policy election in
accordance with ASC 480-10-S99-3A and recognizes changes in redemption value in accumulated deficit over an expected 9-month period leading
up to a Business Combination.
Note 4 — Private
Placement
Simultaneously with the closing of the IPO, the
Sponsor purchased 260,500 Private Units at a price of $10.00 per Private Unit for an aggregate purchase price of $2,605,000 in a private
placement. Simultaneously with the closing of the over-allotment option, the Company consummated the sale of an additional 8,873 Private
Units with the Sponsor at a price of $10.00 per Private Unit, generating total proceeds of $88,725. Each Private Unit consists of one
share of common stock (“Private Share”), one right (“Private Right”) and one redeemable warrant (“Private
Warrant”). Each Private Right will convert into one-tenth (1/10) of one share of common stock upon the consummation of a Business
Combination. Each Private Warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to
adjustment. The Private Warrants will be identical to the Public Warrants except that the Private Warrants and the shares of common stock
issuable upon the exercise of the Private Warrants will not be transferable, assignable or salable until after the completion of a Business
Combination. The net proceeds from the Private Units were added to the proceeds from the IPO to be held in the Trust Account. If the Company
does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Units will be used to
fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Units and all underlying securities
will expire worthless.
Note 5 — Related Party
Transactions
Founder Shares
On September 25, 2021, the Company issued
1,437,500 shares of common stock to the Initial Stockholders (the “Founder Shares”) for an aggregated consideration of $25,000,
or approximately $0.017 per share.
The Initial Shareholders have agreed to forfeit up to up to 187,500
Founder Shares to the extent that the underwriters’ over-allotment is not exercised in full, so that the Initial Stockholders will
collectively own 20% of the Company’s issued and outstanding shares after the IPO (assuming the Initial Stockholders do not purchase
any Public Shares in the IPO and excluding the Private Units). As a result of the underwriter’s partial exercise of the over-allotment
option on October 4, 2022, 119,250 shares of the Founder Shares were forfeited for no consideration on October 7, 2022 resulting in 1,318,250
Founder Shares outstanding after the forfeiture.
The Initial Stockholders have agreed, subject
to certain limited exceptions, not to transfer, assign or sell any of their Founder Shares until, with respect to 50% of the Founder Shares,
the earlier of six months after the consummation of a Business Combination and the date on which the closing price of the common
stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like)
for any 20 trading days within a 30-trading day period commencing after a Business Combination and, with respect to the
remaining 50% of the Founder Shares, until the six months after the consummation of a Business Combination, or earlier, in either
case, if, subsequent to a Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction
which results in all of the Company’s stockholders having the right to exchange their shares of common stock for cash, securities
or other property.
Promissory Note — Related
Party
On September 5, 2021, the Sponsor agreed
to loan the Company up to an aggregate amount of $200,000 to be used, in part, for transaction costs incurred in connection with the IPO
(the “Promissory Note”). The Promissory Note is unsecured, interest-free and due on the closing of the IPO. The Company repaid
the outstanding balance of $200,000 to the Sponsor on October 7, 2022.
The Company received $155,025 from the Sponsor
at the closing of IPO to finance transaction costs in connection with searching for a target business. On October 7, the Sponsor converted
the outstanding balance of $155,025 to the Promissory Note. The Promissory Note is unsecured, interest-free and due on the earlier of
June 29, 2023 or the date the Company consummates a business combination. As of December 31, 2022 and 2021, $155,025 and $200,000 were
outstanding under the Promissory Note, respectively.
On March 22, 2023, the Sponsor loaned the Company
$200,000, to be used, in part, for transaction costs related to the Business Combination.
Related Party Loans
In addition, in order to finance transaction costs
in connection with searching for a target business or consummating an intended initial business combination, the initial stockholders,
officers, directors or their affiliates may, but are not obligated to, loan the Company funds as may be required. In the event that the
initial business combination does not close, the Company may use a portion of the working capital held outside the trust account to repay
such loaned amounts, but no proceeds from the Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible
into units at a price of $10.00 per unit at the option of the lender. The terms of such related party loans, if any, have not been determined
and no written agreements exist with respect to such loans.
As of December 31, 2022, the Company had no borrowings
under the working capital loans.
Administrative Services Agreement
The Company entered into an Administrative Service
Agreement, commencing on the effective date of the IPO through the earlier of the Company’s consummation of a Business Combination
and its liquidation, to pay the Sponsor a total of $10,000 per month for office space, administrative and support services. The monthly
fees will be ceased upon completion of an initial Business Combination or liquidation. For the year ended December 31, 2022 and the period
from May 6, 2021 (inception) to December 31, 2021, the Company incurred $28,387 and none, respectively, in fees for these services, of
which $28,387 and none are included in accrued expenses in the accompanying balance sheets as of December 31, 2022 and 2021, respectively.
Note 6 — Commitments and
Contingency
Registration Rights
The holders of the Founder Shares, Private Units (and
all underlying securities), and any shares that may be issued upon conversion of working capital loans will be entitled to registration
rights pursuant to a registration rights agreement signed on the effective date of IPO. The holders of the majority of these securities
are entitled to make up to three demands that the Company register such securities. The holders of the majority of the Founder Shares
can elect to exercise these registration rights at any time commencing three months prior to the date on which the Founder Shares
are to be released from escrow. The holders of a majority of the Private Units and units issued in payment of working capital loans
made to the Company can elect to exercise these registration rights at any time commencing on the date that the Company consummates a
Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration
statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with
the filing of any such registration statements.
Underwriting Agreement
The Company has granted Ladenburg Thalmann, the
representative of the underwriters, a 45-day option from the date of this prospectus to purchase up to 750,000 additional Units to
cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On October 4, 2022, the underwriters
partially exercised the over-allotment option to purchase 273,000 units which was closed on October 7, 2022, generating gross proceeds
to the Company of $2,730,000.
The underwriters were paid a cash underwriting discount of 1.75% of
the gross proceeds of the IPO, or $922,775. In addition, the underwriters are entitled to a deferred fee of 4.00% of the gross proceeds
of the IPO, or $2,109,200, which will be paid upon the closing of a Business Combination from the amounts held in the Trust Account, subject
to the terms of the underwriting agreement.
Note 7 — Stockholders’ Equity
Common Stock — The Company is authorized to issue 16,000,000 shares of common stock
with a par value of $0.0001 per share. Holders of the common stock are entitled to one vote for each share. As of December 31, 2021, there
were 1,437,500 shares of common stock issued and outstanding, of which an aggregate of up to 187,500 Founder Shares are subject to forfeiture
to the extent that the underwriters’ over-allotment is not exercised in full, so that the Initial Stockholders will collectively
own 20% of the Company’s issued and outstanding shares after the IPO (assuming the Initial Stockholders do not purchase any Public
Shares in the IPO and excluding the Private Units). As a result of the underwriter’s partial exercise of the over-allotment option
on October 4, 2022, 119,250 shares of the Founder Shares were forfeited for no consideration on October 7, 2022. As of December 31, 2022,
there were 1,662,623 shares of common stock issued and outstanding (excluding 5,273,000 shares subject to possible redemption).
Rights — Each holder
of a right will receive one-tenth (1/10) of one share of common stock upon consummation of a Business Combination, even if the holder
of such right redeemed all shares held by it in connection with a Business Combination. No fractional shares will be issued upon conversion
of the rights. No additional consideration will be required to be paid by a holder of rights in order to receive its additional shares
upon consummation of a Business Combination, as the consideration related thereto has been included in the Unit purchase price paid for
by investors in the Initial Public Offering. If the Company enters into a definitive agreement for a Business Combination in which the
Company will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share
consideration the holders of the common stock will receive in the transaction on an as-converted into common stock basis and each holder
of a right will be required to affirmatively convert its rights in order to receive one-tenth (1/10) of one share underlying each right
(without paying additional consideration). The shares issuable upon conversion of the rights will be freely tradable (except to the extent
held by affiliates of the Company).
If the Company is unable to complete a Business
Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive
any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of
the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure
to deliver securities to the holders of the rights upon consummation of a Business Combination. Additionally, in no event will the Company
be required to net cash settle the rights. Accordingly, holders of the rights might not receive the shares of common stock underlying
the rights.
Warrants — Each
redeemable warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per share, subject to
adjustment as described in this prospectus. The warrants will become exercisable on the later 30 days following the completion
of an initial Business Combination and 12 months from the date of this prospectus. The Company has agreed that as soon as
practicable, but in no event later than 15 business days after the closing of a Business Combination, the Company will use
its best efforts to file, and within 60 business days following a Business Combination to have declared effective, a
registration statement covering the common stock issuable upon exercise of the warrants. Notwithstanding the foregoing, if a
registration statement covering the issuance of the common stock issuable upon exercise of the Public Warrants is not effective
within a specified period following the closing of the Company’s initial Business Combination, warrant holders may, until such
time as there is an effective registration statement and during any period when the Company shall have failed to maintain an
effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under
the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a
cashless basis. The warrants will expire five years from the closing of the Company’s initial Business Combination at
5:00 p.m., New York City time or earlier upon redemption.
The Company may redeem the outstanding warrants:
| ● | in whole and not in part; |
| ● | at a price of $0.01 per warrant; |
| ● | upon a minimum of 30 days’ prior written notice
of redemption, which the Company refers to as the 30-day redemption period; |
| ● | if, and only if, the last reported sale price of the Company’s
common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and
the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the
date on which the Company sends the notice of redemption to the to the warrant holders. |
If the Company calls the Public Warrants for redemption,
management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,”
as described in the warrant agreement. In such event, each holder would pay the exercise price by surrendering the warrants for that number
of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying
the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined
below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common
stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption
is sent to the holders of warrants.
Except as described above, no warrants will be
exercisable and the Company will not be obligated to issue common stock unless at the time a holder seeks to exercise such warrant, a
prospectus relating to the common stock issuable upon exercise of the warrants is current and the common stock have been registered or
qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of
the warrant agreement, the Company has agreed to use its best efforts to meet these conditions and to maintain a current prospectus relating
to the common stock issuable upon exercise of the warrants until the expiration of the warrants. However, the Company cannot assure that
it will be able to do so and, if the Company does not maintain a current prospectus relating to the common stock issuable upon exercise
of the warrants, holders will be unable to exercise their warrants and the Company will not be required to settle any such warrant exercise.
If the prospectus relating to the common stock issuable upon the exercise of the warrants is not current or if the common stock is not
qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, the Company will not be required
to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and
the warrants may expire worthless.
The Private Warrants have terms and provisions
that are identical to those of the warrants being sold as part of the units in the IPO except that the Private Warrants will be entitled
to registration rights. The Private Warrants (including the common stock issuable upon exercise of the Private Warrants) will not be transferable,
assignable or salable until 30 days after the completion of our initial business combination except to permitted transferees.
Note 8 — Fair Value Measurements
The fair value of the Company’s financial
assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale
of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the
measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of
observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions
about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities
based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1: |
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. |
|
|
Level 2: |
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. |
|
|
Level 3: |
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
The following table presents information about
the Company’s assets that are measured at fair value on a recurring basis at December 31, 2022 and indicates the fair value hierarchy
of the valuation inputs the Company utilized to determine such fair value. There were no marketable securities held in trust account at
December 31, 2021.
| |
December 31, 2022 | | |
Quoted Prices in Active Markets (Level 1) | | |
Significant Other Observable Inputs (Level 2) | | |
Significant Other Unobservable Inputs (Level 3) | |
Assets | |
| | |
| | |
| | |
| |
Marketable securities held in trust account | |
| 53,958,681 | | |
| 53,958,681 | | |
| — | | |
| — | |
Note 9 — Income Taxes
The Company’s net deferred tax assets (liabilities) are as follows:
| |
December 31, | | |
December 31, | |
| |
2022 | | |
2021 | |
Deferred tax asset | |
| | |
| |
Startup/Organization Expenses | |
$ | 36,681 | | |
$ | 826 | |
Unrealized gain on investment held in Trust Account | |
| (36,164 | ) | |
| — | |
Net deferred tax asset | |
| 517 | | |
| 826 | |
Valuation allowance | |
| (36,681 | ) | |
| (826 | ) |
Deferred tax liability, net of allowance | |
$ | (36,164 | ) | |
$ | — | |
The income tax provision consists of the following:
| |
For the year ended December 31, 2022 | | |
For the period from May 6, 2021 (inception) to December 31, 2021 | |
Federal | |
| | |
| |
Current | |
$ | 46,115 | | |
$ | — | |
Deferred | |
| 309 | | |
| (826 | ) |
State | |
| | | |
| | |
Current | |
| — | | |
| — | |
Deferred | |
| — | | |
| — | |
Change in valuation allowance | |
| 35,855 | | |
| 826 | |
Income tax provision | |
$ | 82,279 | | |
$ | — | |
A reconciliation of the Company’s statutory
income tax rate to the Company’s effective income tax rate is as follows:
| |
For the
year ended
December 31,
2022 | | |
For the
period from
May 6,
2021
(inception) to
December 31,
2021 | |
Income at U.S. statutory rate | |
| 21.0 | % | |
| 21.0 | % |
State taxes, net of federal benefit | |
| 0.0 | % | |
| 0.0 | % |
Change in valuation allowance | |
| 16,9 | % | |
| (21.0 | %) |
| |
| 37.9 | % | |
| 0.0 | % |
As of December 31, 2022 and 2021, the Company did not have any U.S.
federal and state net operating loss carryovers available to offset future taxable income.
In assessing the realization of the deferred tax assets, management
considers whether it is more likely than not that some portion of all of the deferred tax assets will not be realized. The ultimate realization
of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing
net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future
taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management
believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established
a full valuation allowance. The change in the valuation allowance was $35,855 and $826 for the year ended December 31, 2022 and for the
period from May 6, 2021 (inception) through December 31, 2021, respectively.
The Company’s tax returns for the year ended December 31, 2022
and for the period from May 6, 2021 (inception) through December 31, 2021 remain open and subject to examination.
Note 10 — Subsequent Events
The Company evaluated subsequent events and transactions that occurred
after the balance sheet date up to the date that the financial statements were issued. Based on the review, management identified the
following subsequent event that require disclosure in the financial statements.
On March 22, 2023, the Sponsor loaned the Company $200,000, to be used,
in part, for transaction costs related to the Business Combination. The Promissory Notes are unsecured, interest-free and due earlier
of June 29, 2023 or the date the Company consummates a business combination.
1269055
1.46
1250000
1401204
0.00
1.23
1250000
1269055
1401204
0.00
1.23
1.46
P5Y
1.69
false
FY
0001894210
0001894210
2022-01-01
2022-12-31
0001894210
2022-06-30
0001894210
2023-03-31
0001894210
2022-12-31
0001894210
2021-12-31
0001894210
2021-05-06
2021-12-31
0001894210
qomo:RedeemableCommonStockMember
2022-01-01
2022-12-31
0001894210
qomo:RedeemableCommonStockMember
2021-05-06
2021-12-31
0001894210
qomo:NonredeemableCommonStockMember
2022-01-01
2022-12-31
0001894210
qomo:NonredeemableCommonStockMember
2021-05-06
2021-12-31
0001894210
us-gaap:CommonStockMember
2021-12-31
0001894210
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001894210
us-gaap:RetainedEarningsMember
2021-12-31
0001894210
us-gaap:CommonStockMember
2022-01-01
2022-12-31
0001894210
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-12-31
0001894210
us-gaap:RetainedEarningsMember
2022-01-01
2022-12-31
0001894210
us-gaap:CommonStockMember
2022-12-31
0001894210
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001894210
us-gaap:RetainedEarningsMember
2022-12-31
0001894210
us-gaap:CommonStockMember
2021-05-05
0001894210
us-gaap:AdditionalPaidInCapitalMember
2021-05-05
0001894210
us-gaap:RetainedEarningsMember
2021-05-05
0001894210
2021-05-05
0001894210
us-gaap:CommonStockMember
2021-05-06
2021-12-31
0001894210
us-gaap:AdditionalPaidInCapitalMember
2021-05-06
2021-12-31
0001894210
us-gaap:RetainedEarningsMember
2021-05-06
2021-12-31
0001894210
srt:MinimumMember
2022-01-01
2022-12-31
0001894210
srt:MaximumMember
2022-01-01
2022-12-31
0001894210
us-gaap:IPOMember
2022-09-26
2022-10-04
0001894210
us-gaap:IPOMember
2022-10-04
0001894210
us-gaap:IPOMember
2022-01-01
2022-12-31
0001894210
us-gaap:IPOMember
2022-12-31
0001894210
qomo:BusinessCombinationMember
2022-12-31
0001894210
us-gaap:OverAllotmentOptionMember
2022-01-01
2022-12-31
0001894210
us-gaap:OverAllotmentOptionMember
2022-09-26
2022-10-04
0001894210
2022-10-04
0001894210
us-gaap:OverAllotmentOptionMember
2022-09-26
2022-10-07
0001894210
us-gaap:PrivatePlacementMember
2022-01-01
2022-12-31
0001894210
2022-10-07
0001894210
qomo:BusinessCombinationMember
2022-01-01
2022-12-31
0001894210
srt:ScenarioForecastMember
2023-03-22
0001894210
2022-08-10
2022-08-16
0001894210
2021-01-01
2021-12-31
0001894210
qomo:RedeemableCommonStockMember
2021-01-01
2021-12-31
0001894210
qomo:NonredeemableCommonStockMember
2021-01-01
2021-12-31
0001894210
2022-10-01
2022-10-04
0001894210
2022-10-01
2022-10-07
0001894210
us-gaap:OverAllotmentOptionMember
2022-10-07
0001894210
us-gaap:NoteWarrantMember
2022-12-31
0001894210
qomo:SponsorMember
2022-12-31
0001894210
us-gaap:PrivatePlacementMember
2022-12-31
0001894210
qomo:PrivateWarrantsMember
2022-12-31
0001894210
2021-09-25
0001894210
qomo:FounderSharesMember
2021-09-25
0001894210
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2022-12-31
0001894210
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2022-01-01
2022-12-31
0001894210
2021-09-01
2021-09-05
0001894210
us-gaap:IPOMember
2022-10-07
0001894210
qomo:UnderwritingAgreementMember
2022-10-01
2022-10-04
0001894210
qomo:UnderwritingAgreementMember
2022-01-01
2022-12-31
0001894210
qomo:WarrantsMember
2022-12-31
0001894210
us-gaap:WarrantMember
2022-12-31
0001894210
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001894210
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001894210
us-gaap:FairValueInputsLevel3Member
2022-12-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure